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ABSTRACT 
THE ROLE OF SMALL PEPTIDES IN 
CANCER PHYSIOLOGY AND CHEMOTHERAPY
Bao-Ling Tsay
Old Dominion University 
and
Eastern Virginia Medical School 
Director: Dr. Lloyd Wolfinbarger, Jr.
The targeting of proven anticancer drugs specifically to cancer cells would 
provide a unique opportunity to restrict neoplasms without damaging the cancer 
patient. The present research utilizes the phenomenon of illicit transport, i.e. the 
coupling of normally impermeant metabolites to permeant metabolites, in 
targeting the drug melphalan to mouse Ehrlich ascites tumor cells. The dipeptide 
beta-alanyl-melphalan was synthesized and tested in vitro for toxicity towards 
mouse Ehrlich ascites tumor cells, mouse liver cells, and mouse 3T3 embryonic 
cells. The parent compound, melphalan, was used as a control treatment. In 
addition, both melphalan and beta-alanyl-melphalan were utilized in in vivo 
chemotherapeutic assays to assess the efficacy of both drugs to restrict tumor cell 
growth in a mouse model system.
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The dipeptide, beta-alanyl-melphalan, was synthesized using standard 
liquid synthesis procedures and assayed for purity and stability by high 
performance liquid chromatography. The peptide was shown to be greater than 
85% pure and was significantly more stable at 37° C than melphalan, exhibiting a 
half-life in solution of 607.71 minutes. The half-life of melphalan under similar 
conditions was 105.21 minutes. The inclusion of proteins in solutions of 
melphalan increased the stability of this drug, providing for a half-life of 176.72 
minutes. Both melphalan and beta-alanyl-melphalan were stable at 0° C.
In in vitro toxicity assays, melphalan was shown to be toxic to all three cell 
systems studied, whereas beta-alanyl-melphalan was toxic only towards the Ehrlich 
ascites tumor cells and the 3T3 fibroblast cells. The dipeptide containing 
melphalan was not toxic to the mouse liver cells at concentrations up to 0.1 mM. 
Toxicity assays included assessment of both plasma membrane permeability and 
cell proliferation after drug treatment. Morphological studies, using scanning and 
transmission electron microscopy as well as light microscopy, of treated cells 
corroborated the toxicity assays, revealing reduced cell numbers, aberrant cell 
morphologies, and cell destruction where drug treatment had been demonstrated 
to alter membrane integrity and/or cell proliferation was observed, i.e. beta- 
alanyl-melphalan treatment of mouse liver cells, cellular morphologies were 
demonstrated to be similar to nontreated liver cells.
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In vivo chemotherapy assays, using Ehrlich ascites tumor cells injected into 
the abdominal cavity of mice, revealed that melphalan, at concentrations of 5 and 
10 mg/kg, was an effective anticancer drug providing for T /C  rations of 179 and 
193 respectively. The dipeptide, beta-alanyl-melphalan, was also an effective 
anticancer drug, exhibiting reduced toxicity towards the tumor bearing animal 
when compared to the parent drug melphalan, providing for T /C  rations of 152 
at a drug concentration of 40 mg/kg. Neither drug had observable effects on 
animal activities, i.e. food and water consumption, yet significantly restricted 
tumor cell growth as assessed by increasing body weights and survival times of 
tumor bearing mice.
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INTRODUCTION
Effective cancer chemotherapy is based on the premise that the anticancer 
agent can be targeted specifically to the cancer cells. One such means of 
targeting cells for potentially toxic compounds lies in the phenomenon of portage 
transport. Portage transport, first reported in a microbial cell system (Escherichia 
colt) led to the demonstration that normally impermeant amino acid analogues 
(which are not recognized by the more stringent amino acid transport systems) 
could be transported into cells when incorporated into the backbone of a peptide 
(Ames et al., 1973). The amino acid analogues are released, after transport, by 
the intense peptidase activity normally found in the cytoplasm. In efforts aimed 
at broadening the scope of portage transport to molecules other than amino acid 
analogues, Boehm (1983) and Perry (1983) described the transport of sulfhydryl 
containing compounds by their attachment through a disulfide bond to the 
cysteine residue of a di- or tripeptide (Boehm et al., 1983; Perry and Gilvarg, 
1983). After transport into Escherichia coli, the sulfhydryl compounds are 
released by disulfide exchange reactions in the sulfhydryl-rich cytoplasm. 
Additional studies reported transport of synthetic dipeptides and oligopeptides 
containing nucleophilic moieties attached to the alpha carbon of a glycine residue
I
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(Kingsbury et al., 1984). These peptides are accepted by the peptide transport 
systems of Escherichia coli and are capable of being hydrolyzed by intracellular 
peptidases. After releasing its amino group the alpha-substituted glycine is 
chemically unstable and decomposes, releasing the nucleophilic moiety. Thus, the 
combination of peptide transport and intracellular peptidase action results in the 
intracellular release of the nucleophile. These findings validated the feasibility 
of using side-chain attachment to facilitate portage transport by peptide transport 
systems of Escherichia coli. These types of synthetic peptides have broad 
applicability to the study of microbial physiology and the development of an 
additional class of antimicrobial agents. This form of metabolite transport relies 
on the ability to couple the transport of normally impermeant molecules to the 
transport of permeant molecules, permitting their accumulation by cells. The 
peptide transport systems described in microorganisms (Payne and Bell, 1977; 
Wolfinbarger and Marzluf, 1975a) and in mammalian cell systems (Mathews,
1975) afford a convenient means for toxic metabolite accumulation.
Studies of peptide transport in microorganisms have been important in that 
they have permitted both biochemical and genetic dissection of peptide and 
amino acid transport systems and have formed the initial basis for the prediction 
of separate transport mechanisms. Most organisms utilize peptides nutritionally 
as sources of amino acids for protein synthesis (Payne and Bell, 1977). In 
bacteria, primarily Escherichia coli which lacks extracellular peptidase 
activities,peptides are transported intact and hydrolyzed intracellularly. The
2
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peptide transport systems of Escherichia coli have been extensively characterized 
and have been shown to include three distinct systems, one for dipeptides, 
another for oligopeptides, and a third for tripeptides (Payne and Nisbet, 1980). 
The dipeptide transport system appears to exhibit a requirement for the 
alpha-amino and alpha-carboxyl groups of structurally dissimilar dipeptides such 
that the residue amino acids contribute little to recognition for transport. 
Oligopeptides are not transported by the dipeptide transport system. Instead, 
oligopeptides are accumulated into bacterial cells by an oligopeptide transport 
system that recognizes a free alpha-amino group and the overall size of the 
oligopeptide, but does not require an intact alpha-carboxyl group. The tripeptide 
transport system appears to prefer peptides composed of amino acids with 
hydrophobic side chains.
The study of peptide transport in eukaryotic microorganisms has been 
confined primarily to yeast and Neurospora crassa. The ascomycetous fungus 
Neurospora crassa appears to possess only an oligopeptide transport system 
requiring a free alpha-amino acid group for transport (Wolfinbarger and Marzluf, 
1975b). The oligopeptide transport system has a  relatively wide specificity for 
short-chain oligopeptides but does not handle dipeptides or free amino acids. 
Neurospora crassa does not grow well on dipeptides unless they are hydrolyzed 
extracellularly to free amino acids nor do dipeptides compete with oligopeptides 
for transport. In addition, the oligopeptide transport system appears not to be 
able to transport peptides larger than a pentapeptide. These studies in
3
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microorganisms have been important in that they have permitted the use of small 
peptides containing antimetabolites in chemotherapy. Thus, a number of research 
groups have shown that microbial transport can be used for delivery of cytotoxic 
amino acid analogues that are not transported by the more stringent amino acid 
transport systems (Boisvert et al., 1986).
The complexity of studying peptide transport in mammalian cell systems has 
restricted the utility of portage transport in vertebrate cell systems. Only three 
tissues have been reported to accumulate small peptides, intestinal mucosal cells 
(Rosen-Levin, et al, 1980; Ganapathy and Mendicino, 1981b), proximal tubule 
epithelial cells in kidney (Carone and Peterson, 1980; Ganapathy and Leibach, 
1982a), and specific tumor cells (Christensen and Rafn, 1952). The tumor cell 
system is of primary interest here, but it is essential that transport of small 
peptides in noncancerous cell systems be considered because of the potential for 
toxic side effects during chemotherapy.
Research in animal cell systems has been confined primarily to studies of 
peptide absorption by mammalian intestine (Matthews, 1975; Scriver, et al., 1975) 
and kidney cortex slices (Adibi, 1977). Many of these studies have used glycine 
containing peptides and confirmed the presence of biochemically distinct peptide 
transport mechanisms in mammalian cell systems. These peptide transport 
systems are distinct from the amino acid transport systems also present in animal 
cells (Benuck, et al., 1981). The resistance of carnosine (beta-alanyl-L-histidine)
4
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to peptidohydrolases has resulted in the use of this peptide in a large number of 
peptide transport studies in small intestine cell systems (Addision, e t al., 1974; 
Matthews, et al., 1974; Adibi and Soleimanpour, 1974). Glycyl-proline also has 
been shown to be highly resistant to hydrolysis by the particulate fraction of small 
intestinal mucosal cells (Ganapathy, et al., 1980). It may be suggested that all 
mammalian cells possess the genetic potential for small peptide transport, but the 
majority of mammalian cells do not transport small peptides suggests that this 
genetic potential is perhaps not normally expressed. Indeed, the premise has 
been advanced that the role of small peptides in the hormonal mediation of 
cellular regulation may require that such cells not be capable of small peptide 
transport. Neoplastic transformation of a cell is known to relieve genetic 
repression of a number of genes in the cancerous cell and thus cancer cells may 
be capable of small peptide transport. This differential ability of cancerous and 
noncancerous cells to transport small peptides should provide the opportunity to 
synthesize small peptides with toxic amino acid analogues which, when injected 
into a cancerous animal, would selectively kill the cancer cells without doing 
significant damage to the animal (Ringrose, 1983).
Peptide transport in mammalian cell systems has been more difficult to study 
than in microbial systems because of large numbers of peptidohydrolytic enzymes. 
Tumor cells typically secrete (Holmberg, 1961; Ottoson, 1960) large numbers and 
levels of such enzymes and the problems experienced by Christensen and Rafn 
(1952) continue to complicate studies on peptide transport and indeed the role
5
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of small peptide hormones in regulation of tumor cell physiology. Significant 
advances in the study of peptide transport in mammalian cells came with the 
introduction of brush-border membrane vesicles obtained from epithelial cells of 
the small intestine (Ganapathy, et al., 1984; Berteloot, 1982) and renal proximal 
tubules (Ganapathy, et al., 1981; Ganapathy and Leibach, 1982). The removal of 
small peptides from solution in both systems (intestine and kidney) and their 
enzymatic degradation may occur by two mechanisms: 1) transport of small 
peptides into the cell with intracellular hydrolysis, or 2) enzymatic cleavage of 
small peptides at the luminal surface with transportation of the products through 
resident amino acid transport systems. Membrane hydrolysis was first described 
in the small intestine, and an extensive literature supports this mechanism 
(Matthews, 1975). The intestinal brush border has a complex microvillar 
structure covered by a trilaminar membrane that is lined on the luminal side by 
the glycocalyx, a branching carbohydrate-rich network of fine filaments. The 
brush border is rich in hydrolytic enzymes and proteins active in transport. Brush 
border enzymes are hydrolases, and include disaccharidases, peptidases, and 
phosphatases, and those that degrade substrate outside the cell are either 
sequestered in the glycocalyx or attached to the external surface of the membrane 
with part of their molecular structure exposed to cell exterior (Alpers and 
Seetharam, 1977; Matthews, 1975; Ugolev, et al., 1977). Hydrolysis of peptides in 
the intestine occurs at several sites. Intraluminal hydrolysis occurs within the bulk 
phase of the fluid in the intestinal lumen (Matthews, 1975). Membrane 
hydrolysis occurs in the brush border by exogenous peptidases adsorbed to the
6
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brush border glycocalyx or by hydrolases in the cell membrane (Alpers and 
Seetharam, 1977; Matthews, 1975; Ugoloev, et al., 1977). Intracellular hydrolysis 
occurs deep in the cell membrane, in the cytosol or within intracellular organelles 
(Josefesson, et al., 1977; Matthews, 1975; Ugolev, et al., 1977). It has been 
established that intraluminal and membrane hydrolysis in the intestine yields a 
mixture of small peptides and amino acids of which peptides predominate 
(Matthews, 1975). Two mechanisms are involved in the uptake of small peptides 
in intestine; membrane hydrolysis followed by intracellular release of amino acids, 
and carrier-mediated absorption of di- and tripeptides with subsequent hydrolysis 
in the cytoplasm (Matthews, 1975). Additional research efforts on this subject 
have been published (Berteloot et al., 1982; Ganapathy and Leibach, 1983; 
Wilson, et al., 1989). Rajendran, et al. (1987) suggested that dipeptides are 
transported by a Na+-dependent, nonconcentrative, carrier-mediated process. 
Tripeptide transport may occur by both diffusional and carrier-mediated processes 
(Wilson, et al., 1989), of which the latter is not energized by a sodium or proton 
gradient.
The fine structure of the brush border membrane of the kidney proximal 
tubule is similar to that of the intestine and is also rich in hydrolytic enzymes. 
Functionally, both membranes have a high capacity to hydrolyze oligopeptides 
and reabsorb amino acids. A number of studies have shown that small peptides 
are hydrolyzed by peptidases associated with the renal brush border membrane 
and the liberated amino acids are absorbed by the Na+-dependent, carrier-
7
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mediated processes known to exist for free amino acids (Silbemagl, et al., 1975; 
Carone and Peterson, 1980). Ganapathy and coworkers (1988) reported for the 
first time that brush border membrane vesicles, prepared from rabbit renal 
cortex, possess a dipeptide system which transports intact glycyl-L-proline by a 
Na+-dependent, carrier-mediated transport. Ganapathy, et al. (1988) further 
characterized the dipeptide transport system using L-camosine, which has greater 
resistance to hydrolysis by rabbit renal brush-border membranes compared to 
glycyl-L-proline. L-camosine was shown to be transported into rabbit renal 
brush-border membrane vesicles by a Na+- independent mechanism. Various di- 
and tripeptides inhibited L-carnosine transport, whereas amino acids did not. 
There was no detectable hydrolysis of L-camosine outside the vesicles and 
intravesicular contents showed a 30% hydrolysis of the peptide within the vesicles. 
Based on the observations, Ganapathy proposed a  model for the transport of 
dipeptides across the bmsh-border membrane of renal epithelial cells. According 
to this model, transport of the intact peptide across the membrane is followed by 
its partial or complete hydrolysis by a membrane peptidase whose active site is on 
the cytoplasmic side of the membrane (Ganapathy, et al., 1982b). In a recent 
publication, Trimppathi, et al. (1990) investigated the transport characteristics of 
L-phenylalanyl-L-prolyl-L-alanine in renal bmsh-border membrane vesicles 
isolated from the Japan Fisher 344 rat. This strain has been described as 
genetically lacking in dipeptidyl peptidase IV activity (Watanable, et al., 1987). 
Dipeptidyl peptidase IV, which is one of the major renal bmsh-border peptidases, 
releases X-Pro or X-Ala type dipeptides from the amino-terminal end of large
8
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peptides. X-Pro-Y sequence type of peptides are almost exclusively hydrolyzed by 
dipeptidyl peptidase IV (Watanable, et al., 1987). These investigators found that 
(a) Phe-Pro-Ala is not hydrolyzed by renal brush-border membrane vesicles 
isolated from Japan Fisher 344 rats, (b) the transport of the tripeptide is in the 
intact form into the vesicles, (c) transport of the tripeptide is active, is driven by 
an inwardly directed H + gradient, is electrogenic, and occurs via the tripeptide- 
proton symport mechanism. This report is the first direct evidence for the 
presence of an electrogenic tripeptide-proton symport peptide transport 
mechanism in renal brush-border membrane (Tiruppathi, et al., 1990).
The uptake of peptides by a free-cell neoplasm was first studied prior to 
1952 by Christensen and Rafn (1952). This study measured the transport of 
seven peptides by Ehrlich mouse ascites carcinoma cells and human and duck 
erythrocytes. The peptides utilized in this study included glycyl-glycine, 
glycyl-glycyl-glycine, L-leucyl-glycine, L-phenylalanyl-glycine, L-tyrosyl-glycine, 
glutathione, and L-glutamyl-L-glutamic acid. The erythrocytes failed to take up 
any of these seven peptides and the neoplastic cells hydrolyzed leucyl-glycine, 
phenylalanyl-glycine, and tyrosyl-glycine too rapidly to permit observation of 
cellular uptake of unsplit peptide. Only glycyl-glycine, glycyl-glycyl-glycine, and 
glutamyl-L-glutamate were reported to be transported intact by the mouse 
carcinoma cells. The uptake of these three peptides was inferior to that of free 
amino acids and, in addition, the peptides were strong inhibitors of amino acid 
uptake without themselves being transported (Christensen and Rafn, 1952).
9
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In a recent publication, Yagi, et al. (1988a) suggested that PTT.119 (a 
tripeptide; jp-fluoro-phenylalanyl-m-bis-(2-chloroethyl)amino-L-phenylalanyl- 
methionine ethoxy HC1) was transported by the MJY-alpha mammary tumor and 
B16 melanoma cell lines via two natural pathways for amino acid transport. 
Covalent linkage of methionine and phenylalanine residues to the bis-(2- 
chloroethyl)amino-phenylalanine molecule yielded a new bifunctional alkylating 
agent, PTT. 119 (p-F-Phe-m-bis-(2-chloroethyl)-amino-L-Phe-Met-ethoxy-HCl).
The primary route of PTT.119 entry was the classical L  system, with the ASC 
system accounting for approximately 5-6% of PTT.119 transport in the B16 
melanoma cells. The L system in mammalian cells preferentially catalyzes the 
uptake of branch-chain and aromatic amino acids, i.e. leucine, isoleucine, 
phenylalanine and valine by a sodium-independent mechanism. The 
nonmetabolizable analog, 2-aminobicyclo-[2,2,l]-heptane-2-carboxylic acid 
(BCH), is an ideal and specific substrate for system L. System ASC is 
sodium-dependent and transports alanine, serine, cysteine and threonine. 
Alpha-aminoisobutyric acid (AIB), is the nonmetabolizable substrate typical used 
for system ASC analysis. Tripeptide (PTT.119) uptake by MJY-alpha mammary 
tumor cells occur only through system L (Yagi, et al., 1988a). Yagi et al. (1988b) 
also investigated the transport of PTT.119 in L1210 leukemia cells. A major 
amino acid transport system in L1210 cells for PTT.119 was the classic 
sodium-independent L system as evidenced by competitive inhibition of BCH 
uptake by PTT.119 in the absence of sodium. A second transport system which
10
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was also involved in PTT.119 uptake was probably the ASC system (Yagi et al. 
1988b). There are no specific substrates which allow discrimination of the ASC 
system. Although threonine has been reported to be highly selective for the 
sodium-dependent ASC system in rat HTC hepatoma cells. Yagi, et al. (1988b) 
suggested that the low level of PTT.119 competition with threonine in the 
presence of sodium indicated that the ASC system probably played a small role in 
PTT.119 transport in L1210 leukemia cells.
Tumor cells typically secrete large numbers of hydrolytic enzymes (Poole, 
1978) and the levels of these enzymes rise in the plasma of animals as the growth 
of the tumor develops (Santesson, 1935). It has been known for many years that 
cultured tumor explants exhibit proteolytic enzyme activity (Fisher, 1946) and the 
suggestion that proteinases play a role in tumor invasion was made by Santesson 
(1935) and Fisher (1946), and prompted the meticulous studies of Sylven and 
Bois-Svenssen (Sylven, 1960) on the localization of enzymes in tumors. With the 
advent of exquisitely sensitive and specific enzyme assays, the whole field of 
proteolysis by tumors has advanced enormously over the last decade (Poole, 1978; 
Strauli, 1980; Mort, 1981).
Proteases (peptide hydrolases; peptidohydrolases) include all enzymes that 
cleave peptide bonds (classified by the Enzyme Commission of the International 
Union of Biochemistry as EC 3.4.). Peptidohydrolytic enzymes are generally 
considered to be divided into proteinases (endopeptidases) and peptidases
11
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(exopeptidases). Proteinases cleave peptide bonds internally in peptides and 
usually cannot accommodate the charged amino- or carboxyl-terminal amino acids 
at the active site. Peptidases reaction is directed by the amino- or 
carboxyl-terminus of the peptide. Proteinases are classified to four classes 
(serine, cysteine, aspartic, metallo) depending on the catalytic mechanisms of 
their active center, which are revealed by the use of inhibitors rather than the 
substrates. Serine proteinases are active at neutral pH values. Serine proteinases 
are abundant in the body and can be active almost anywhere; hence the need for 
"control" systems. Most of the serine proteinase are synthesized as inactive 
precursors that require limited proteolysis to activate them. This provides a 
convenient form of enzyme for storage, as in the pancreatic zymogen granules, 
and also allows control systems with positive feedback, such as the activation of 
trypsinogen by trypsin, and "cascade" control systems as in blood coagulation 
factors (Davie, et al., 1979). Two similarly related serine proteinases that have 
been of particular interest in relation to the growth of cancer cells are plasmin 
and plasminogen activator (Moscatelli, et al., 1980). The plasmin formed by the 
activation of plasminogen by plasminogen activator may function to degrade 
elements of the surrounding tissue, thereby permitting invasion by tumor 
(Quigley, et al., 1974). A study of the correlation between malignant 
transformation and increased plasminogen activator synthesis or secretion in a 
variety of cell lines has shown that both adenomas and carcinomas have higher 
plasminogen activator activity levels than normal mucosa (Suzumiya, et al.,
1988). The second form of control of serine proteinases is protein inhibitors.
12
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About 10% of human plasma protein consists of serine proteinase inhibitors, the 
most abundant of which are alpha 1-proteinase and alpha 2-macroglobulin 
(Keohane, et al., 1990).
Lysosomal cysteine proteinases are active at pH 6 and unstable above pH 7. 
Cathepsin B is the most studied of the mammalian cysteine-proteinases. This 
enzyme was suggested by Sylven (1974) to be involved in cellular detachment and 
subsequent metastasis of tumors. Cathepsin B is a lysosomal cysteine protease 
that may play a role in the activation of extracellular degrading enzymes involved 
in the destruction of the subendothelial matrix and extravasation of metastatic 
tumor cells.
A cellular cysteine proteinase with properties very different from the 
lysosomal cysteine proteinases is the Ca++-dependent proteinase first discovered 
in skeletal muscle (Dayton, et al., 1975) and then in brain, liver and other tissues 
(Puca, et al., 1977; Reville, et al., 1976; Takai, et al., 1977). This enzyme occurs 
in the cytoplasm, and is most active at neutral pH, in the presence of a thiol 
compound and calcium ions. Many studies of malignant cells or neoplastic tissue 
in culture have implicated cysteine proteases in the progression of malignancy 
(Sheahan, et al., 1989). Both cathepsin B-like and cathepsin L-like cysteine 
protease specific activities were significantly elevated in the carcinoma tissue. 
Correlation of cathepsin B-like and L-like cysteine protease activities in 
individuals with different stages of colorectal cancer demonstrated significantly
13
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higher cysteine protease activities in individuals with Dukes A tumors (tumors 
confined to the bowel wall) than in patients with more advanced tumors (Dukes’ 
B, C, or D tumors). These results implied an important role for cysteine 
proteases in the early progression of human colorectal carcinoma (Sheahan, et al.,
1989). Keren and LeGrue (1988) also reported the presence of cathepsin B-like 
enzyme activity on the surface of tumor cell variants expressing both high and low 
metastatic potentials demonstrating that all tumor lines had detectable cathepsin 
B-like enzymes which may play a role in the activation of extracellular degrading 
enzymes involved in the destruction of the subendothelial matrix and 
extravasation of metastatic tumor cells.
Aspartic proteinases have not been identified in prokaryotes, but are present 
in eukaryotes. In mammalian systems, several extracellular aspartic proteinases 
have been well studied: the pepsins (from the gastric juice of many species), 
chymosin (from calf stomach), and renin (from kidney and plasma of many 
species). The most studied of the aspartic proteinases is pepsin, or rather the 
family of related pepsins responsible for the digestion of food proteins in the 
strongly acidic conditions of the stomach. Cathepsin D, the cathepsin first 
studied in detail by Anson (1940), is by far the most easily detectable lysosomal 
aspartic proteinase. Cathepsin D has limited action against native proteins but 
possesses considerable activity against denatured proteins at pH 3.5-5. The 
enzyme preferentially attacks peptide bonds flanked by hydrophobic amino acids, 
i.e. phe-phe, phe-tyr, leu-phe (von Figura and Hasilik, 1986) and it has been
14
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proposed that cathepsin D plays a role in pathological degradation of central 
nervous system proteins such as myelin basic protein (Whitaker and Seyer, 1979).
Metallo-proteinases are widely distributed in prokaryotes and eukaryotes. 
Mammalian metallo-proteinases have been identified extracellularly, in cell 
membrane (plasma and endoplasmic reticulum), and in cytosol (Bond and 
Beynon, 1985). These extracellular enzymes include collagenases, gelatinases, and 
procollagen N-proteinase. These enzymes preferentially cleave peptides with 
hydrophobic amino acid residues (Chu and Orlowski, 1985). Neutral to slightly 
alkaline pH  is preferred for maximal activity of the metallo-proteinases, which are 
also sensitive to thiols. There have been studies of collagenase in relation to a 
variety of tumors (Woolley, et al., 1980). Most mammalian tissue collagenases 
require preliminary proteolytic activation in order for activities to be detected in 
in vitro assays. Kao and Stern (1986) compared collagenases from breast 
carcinoma and human stromal cells. It is the malignant epithelial cells and not 
the stromal cells that are the major source of collagenolytic activity, and this 
activity is not dependent on an interaction between the two cell types. Maslow 
(1987) showed that the motility of tumor cells is enhanced by exposure to 
exogenous collagenase independent of its effect on collagen-containing 
extracellular matrix. Several studies have indicated that stromal collagens as well 
as the extracellular matrix glycoproteins laminin and fibronectin are chemostatic 
for tumor cells (Terranova and Lyall, 1986; Nekeshima, et al., 1986). Terranova, 
et al (1989) further examined the effect of various proteases involved in
15
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connective tissue degradation on tumor cell motility and found that type I 
collagen- and type IV collagen-specific collagenases, collagen, and collagen 
degradation products are stimuli for the directed migration of tumor cells. They 
also demonstrated that other proteases, specifically plasminogen and plasminogen 
activator (urokinase), which are involved in collagen activation and basement 
membrane degradation, also influence the directed migration of tumor cells 
(Terranova, et al., 1989). All extracellular matrix and especially basement 
membranes are thought to act as barriers to the invasion of tumor cells and to be 
the major connective tissue obstacles for metastatic spread (Liotta, 1984). The 
degradation of these matrices involves the action of proteolytic enzymes, and 
collagenases are believed to be of major importance in the degradation of this 
collagen-rich material (Liotta et al., 1982). The demonstration that B16 
melanoma cells with higher lung colonization potentials have greater collagen- 
degrading activity and that metastatic tumors alone were capable of degrading 
type IV collagen present only in basement membrane (Liotta et al., 1980) focused 
additional attention on the degrading role of collagenases in metastasis.
Many of the early studies critically reviewed by Recklies and Poole 
(Recklies, 1982) showed that a variety of tumors contained enzymes capable of 
producing connective tissue degradation and thereby facilitating invasion. The 
evidence that proteolytic degradation of basement membrane (BM) plays a role 
in invasion includes the undisputed facts that tumor cells can actively degrade BM 
(Liotta, 1986) or BM-related products (DiStefano, 1985) in vitro: that purified
16
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proteases have been derived from tumor cells that degrade BM collagen (Liotta, 
et al., 1981); and that protease inhibitors block or partially inhibit invasion in 
some model systems (Liotta, et al., 1981). Based on work in Liotta’s laboratoiy, 
it appears that many metastatic cells bind preferentially to basement membrane 
(type IV) collagen by using basement membrane laminin as a  attachment protein. 
These cells also produce a distinct collagenase that is able to degrade basement 
membrane (type IV) collagen. The ability of plasma proteinase inhibitors to 
prevent tissue destruction is determined not only by their presence in plasma and 
their affinities for proteinases, but most importantly by their ability to diffuse 
into the extravascular space (Heimburger, 1975; Travis, 1978). A firm indication 
that certain plasma proteinase inhibitors play a role in protecting tissues from 
proteolytic attack is derived from studies of proteinase enzymes. The 
proteinase/plasma proteinase complexes are found at sites of tissue destruction 
(Ohlssin, 1976).
What role does peptide/protein transport and hydrolysis play in the growth 
and development of cancers? Are tumor cells resistant to regulation by peptide 
hormones because the tumor cells transport and/or degrade them prior to their 
acting? Are the peptides liberated by peptidohydrolytic enzymes useful as a 
nutrient in tumor cell growth? Provided tumor cells possess peptide transport 
systems, can we take advantage of this activity? These are the questions we were 
trying to answer.
17
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The peptide transport differences elaborated among mammalian cells should 
provide the opportunity to synthesize small peptides containing toxic amino acid 
analogues which when injected into a cancerous animal should selectively kill the 
cancerous cells without doing significant damage to noncancerous cells. The 
potential for using peptides containing toxic metabolites in cancer chemotherapy 
was described in the early 1950’s by Bergel and Stock (1954) and Larionov, et al 
(1955). Bergel and Stock (1954) attempted to enhance the anticancer potential of 
nitrogen mustard by synthesizing the bis-(2-chloroethyl)-amino-DL-phenylalanine 
derivative which they called mefphalan. Melphalan was synthesized with the hope 
that the incorporation of phenylalanine, a precursor of melanin, into the molecule 
would give the compound some selectivity of action against melanoma. Larionov, 
et al. (1955) synthesized an oligopeptide of sarcolysine (3-p-bis-(2-chloroethyl) 
aminophenyl-D,L-alanine) and studied it for its anticancer activities. They 
reported that an increase in the specificity of sarcolysine for certain tumor cells 
resulted from substitution of the methyl group of nitrogen mustard with 
phenylalanine. Nyhan (1960) subsequently hypothesized that p-sarcolysine 
possessed dual alkylator-antimetabolite activities, since the compound specifically 
inhibited incorporation of amino acid precursors in tumor cells. Further, 
examination of the racemic mixture of p-sarcolysin revealed that the L form 
(melphalan or L-PAM) was the active isomer (Schmidt, 1965).
The alkylating agent HN2 (nitrogen mustard) is transported by an active, 
carrier-mediated process that is shared with choline in murine L5178Y
18
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lymphoblasts (Goldenberg, et al., 1970; Goldenberg et al., 1971). HN2 transport 
was not competitively inhibited by other alkylating agents, including melphalan, 
chlorambucil, trenimon [2,3,5-tris(ethyleneimino)-l,4-benzoquinone], mitomycin C, 
and intact enzyme-activated cyclophosphamide (Goldenberg, 1975). Similarly, 
cyclophosphamide transport was not altered by melphalan, chlorambucil, HN2, or 
isophosphamide (Goldenberg, et al., 1974). These observations indicate that 
uptake of several alkylating agents occurs by independent transport mechanisms 
(Goldenberg, 1975; Goldenberg, et al., 1974; Goldenberg, et al., 1970).
Melphalan transport by L5178Y lymphoblasts was shown to be mediated by a 
carrier mechanism independent of that utilized by other alkylating agents 
(Goldenberg, et al., 1977). Vistica, et al. (1978, 1979) showed that melphalan and 
the amino acid leucine share a common transport system in murine L1210 
leukemia cells.
The mechanism of melphalan uptake by murine LPC-1 plasmatoma cells was 
investigated by Goldenberg et al. (1979). Evidence indicated that melphalan 
uptake is an active process in that uptake of melphalan that proceeds "uphill" 
against a concentration gradient, is temperature- and sodium-dependent, and is 
inhibited by several metabolic antagonists (i.e. antimycin A, oligomycin, 
m-chlorophenyl carbonyl cyanide hydrazone, p-hydroxymercuribenzoate and 
ouabain). Other findings indicate that melphalan uptake is carrier-mediated by 
two separate and distinct amino acid transport carriers. Melphalan uptake by one 
component was inhibited by BCH, but was unaffected by Na+ depletion, which
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appeared to be mediated by system L. Melphalan uptake by the other 
component was Na+-dependent, unaffected by BCH, AIB or Me-AIB, and was 
inhibited by alanine, serine, cysteine, phenylalanine, glutamine and leucine, 
suggesting an involvement of the ASC system (Goldenberg, et al., 1979).
These findings stimulated development of chemotherapeutic agents 
composed of synthetic peptides with cytotoxic activity due to the alkylating group 
and selective carrier function towards specific target cells resulting from linkage 
of various amino acid residues (De Barbieri, 1972). Research efforts were 
continued at the Instituto Sierotherapico Milanese Serafino Belfanti (I.S.M.) 
under the direction of Dr. De Barbieri and resulted in synthesis of hundreds of 
peptides, numerous publications on this subject (De Barbieri, 1983) and eventual 
development of a combination of the most effective peptides into a formulation 
known as peptichemio (De Barbieri, 1972). Reductions in growth of established 
tumors were observed without adverse physiologic, histologic or enzymatic 
alterations in principal organs and tissue of the host.
In a recent publication, De Barbieri (1983) reported on the cancerocidal 
activity of a synthetic tripeptide mustard p-fluoro-phenylalanyl-m-bis-(2- 
chloroethyl) amino-phenylalanyl-methionine ethoxy hydrochloride), PTT.119, 
against a broad spectrum of virulent leukemia. PTT.119 was able to induce a 
dose-dependent, irreversible loss of murine, primate, and human cancer cell 
survival in in vitro systems (De Barbieri, 1983). 'Phis work was quickly followed
20
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
by reports of research conducted in the United States on the potential for 
PTT.119 in killing cancer cells (Yagi et al., 1984a; 1984b). These later studies 
evaluated the therapeutic potential of this synthetic tripeptide by assessing the 
tumorigenicity of L1210 leukemia, MJY-alpha mammary tumor cells exposed to 
PTT.119. Treatment with physiological dosages of PTT.119 effectively reduced or 
completely eliminated tumorigenicity of the tumor cells.
The research to be described here represents a continuation of this effort and 
is divided into parts: I. Basic morphology of mouse Ehrlich ascites tumor cells, 
mouse liver cells, and mouse 3T3 embryonic cells to provide basic information of 
these three cell lines. II. Growth curves and population doubling times to 
provide the basic information on these three cell lines grown in cell culture. III. 
Peptidohydrolytic enzyme activity assays to characterize the numbers and kinds of 
peptidohydrolytic enzymes which are associated with mouse Ehrlich ascites tumor 
cells in the abdominal cavity of mice. IV. Synthesis and purification of a 
dipeptide (beta-alanyl-melphalan) containing the alkylating agent melphalan as 
the toxic antimetabolite. V. Chemical stability of melphalan and beta-alanyl- 
melphalan. VI. Reactivity of melphalan and beta-alanyl-melphalan toward 
peptidohydrolytic enzymes. VII. In vitro toxicity testing of melphalan and beta- 
alanyl-melphalan. VIII. In vitro survival curve testing of mammalian cells 
treated with melphalan and beta-alanyl-melphalan. IX. Morphological studies 
describing the effects of drug treatment on mouse Ehrlich ascites tumor cells and 
mouse liver cells (using a scanning electron microscope, a light microscope, and a
21
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transmission electron microscope). X. In vivo chemotherapy.
The objective of research presented here was to evaluate the potential role of 
small peptides in cancer physiology and chemotherapy.
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MATERIALS AND METHODS
CELL CULTURES. Three cell lines, mouse Ehrlich ascites tumor cells, mouse 
liver cells, and mouse 3T3 embryonic cells were maintained in cell culture at 37° 
C in a humidified incubator gassed with 4% C 0 2. The culture medium was 
routinely changed twice a week.
Mouse Ehrlich ascites tumor cells (Tsay strain) were derived by selection 
culture as a substrain of an original mouse Ehrlich ascites tumor cell line, which 
were the generous gift of Dr. Margaret Neville, University of Colorado (Denver). 
This cell line (Neville) was routinely maintained by serial subculture in the 
abdominal cavity of CF-1 albino mice. Tumor cells were transferred from the 
abdominal cavity of CF-1 mice into culture flasks containing NCTC-135 medium 
supplemented with 10% heat-inactivated fetal bovine serum (Gibco). 
Contaminating red blood cells and lymphocytes were typically lost from the 
culture with the first media change since they fail either to attach or proliferate 
under these culture conditions. By repeated passage, a subline (the "Tsay" strain) 
was established which grew well in tissue culture and maintained the capacity to 
proliferate in the abdominal cavity of a CF-1 albino mouse. The
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Tsay strain of mouse Ehrlich ascites tumor cells were used in all experiments 
described in this study.
The mouse liver cell line (ATCC CCL 9.1), obtained from the American 
Type Culture Collection (ATCC), was routinely cultured in NCTC-135 medium 
(Gibco) supplemented with 10% heat-inactivated horse serum (Gibco). 
Subcultures were prepared by scraping, using a sterile rubber policeman. Old 
medium was removed and fresh medium was added before dislodging cells from 
culture flasks. Cells were transferred to new flasks for subculture. The passage 
number of mouse liver cells utilized in the assays were p l5  (initial passage 
number) to p20.
Balb/3T3 mouse embryonic cell line (ATCC CCL 163) obtained from the 
American Type Culture Collection (ATCC), was routinely cultured in Dulbecco’s 
modified Eagle’s medium (Gibco) containing 10% calf serum (Gibco). This cell 
line was routinely passaged (for 4 to 5 passages) by trypsinization (0.25% trypsin, 
0.02% EDTA, Gibco) and split into new flasks before reaching confluence.
Mouse 3T3 embryonic cells were used at passage 18 to 25 (18 was the passage 
number when obtained from the ATCC).
CRYOPRESERVATION OF CELL LINES. Cell cryopreservation was performed 
on mouse liver cells and mouse 3T3 embryonic cells. Mouse liver cells were 
harvested by scraping, and centrifuged at 2,000 rpm for 5 min. Cell pellets were
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then resuspended in cryopreservation medium ( 10% horse serum and 5% 
dimethyl sulfoxide in NCTC-135 medium) to a cell density of approximately 5 
million cells per ml. Mouse 3T3 embryonic cells were harvested using trypsin and 
centrifuged at 2,000 rpm for 5 minutes. Cell pellets were then resuspended in 
cryopreservation medium (10% calf serum and 5% dimethyl sulfoxide in 
Dulbecco’s modified Eagle’s medium) to a cell density of approximately 5 million 
cells per ml. Cell suspensions were dispensed as 1 ml aliquots into sterile 
Cryogenic vials (Corning), placed in a refrigerator (4° C) for 30 minutes, and then 
into a freezer (-20° C) for 60 minutes, and finally the cells were stored at -80° C.
GROWTH CURVE DETERMINATION. For all three cell lines, known numbers 
of exponentially growing cells were seeded into 35 mm cell culture petri dishes 
containing a known quantity of the appropriate medium, supplemented with 10% 
appropriate serum. Cell cultures were incubated in a humidified C 0 2 incubator 
at 37° C with 4% C 0 2. Twice each day, for 3 to 5 days, triplicate flasks of cells 
were sampled. The total cell counts were determined using a hemocytometer and 
plotted relative to the sample time. The length of time required for a cell 
population to increase by a factor of 2 is the population doubling time (TD). The 
number of cells at the plateau phase (or stationary phase) of growth is the 
saturation density. The average population doubling times and saturation 
densities of the three cell lines are reported.
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ANALYSIS OF INTRACELLULAR AND EXTRACELLULAR PEPTIDO­
HYDROLYTIC ENZYME ACTIVITIES.
Cell Extract Preparations: Mouse Ehrlich ascites tumor cells (Tsay strain) were 
used in peptidohydrolytic enzyme activity assays. Mice were injected 
intraperitoneally with approximately 1 million cells. After 10 to 12 days, the 
mice were killed by cervical dislocation. The Ehrlich ascites tumor cells were 
then removed from the abdominal cavity of the mouse, transferred to centrifuge 
tubes and pelleted by centrifugation using an EEC table top centrifuge (2,000 
rpm). The supernatant, which constitutes the ascites fluid, was then transferred 
into Oak Ridge centrifuge tubes and put on ice for further preparation of the 
extracellular extract. The cell pellet which contained tumor cells, red blood cells, 
and lymphocytes, was resuspended in hypotonic buffer (0.1 M Tris-HCl, 0.01 M 
NaCl, 0.0015 M MgCl2, pH 7.4) and recentrifuged at 2,000 rpm for 5 minutes.
The red blood cells and lymphocytes ruptured in the hypotonic buffer due to 
osmolarity differences and the supernatant, which contained buffer and ruptured 
red blood cells and lymphocytes, were discarded and replaced with fresh 
hypotonic buffer. This procedure was repeated until a "pure white" population of 
tumor cells was obtained (usually two times). The tumor cell suspension was 
centrifuged at 2,000 rpm for 5 minutes to pellet the tumor cells. The supernatant 
was discarded and replaced with Dulbecco’s phosphate buffered saline (DPBS) at 
1:1 (v:v; cell pellettDPBS). The tumor cell suspension was then transferred to a 
tissue homogenizer (PYREX, No. 7727), and homogenized on ice for 15 strokes.
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The cell homogenate was transferred into Oak Ridge centrifuge tubes and put on 
ice for further preparation of the intracellular extract.
The extracellular ascites fluid from the original cell suspension and the 
intracellular extract from the cell pellet were centrifuged separately at 14,000 rpm 
for 30 minutes at 4° C using a JA-17 rotor in a Beckman J2-21 refrigerated 
centrifuge. The supernatants (approximately 10 ml) were transferred into a 
dialysis membrane tubing (SPEC 1KAPOR, m.w. cutoff approximately 3,500) and 
dialyzed against 1 liter of 0.2M Tris-HCl buffer, pH 7.4, at 0° C in the cold room 
overnight with stirring. Protein concentrations were determined by the method of 
Lowry (Lowry et al. 1951) using bovine serum albumin (BSA) as a standard.
Polyacrylamide Gel Electrophoresis with in situ Staining: A separating gel of 
7.5% cyanogum 41 (a mixture of 95% acrylamide and 5% N,N’-methylene-bis- 
acrylamide; Sigma Chem. Co.) was prepared in 35ml of 0.5M Tris-HCl buffer, pH 
8.9, with 16.8 mg L-amino acid oxidase (Type I crude dried venom from Crotalus 
adamanteus, 0.48 units/mg solid. One unit will oxidatively deaminate 1.0 umole 
L-phenylalanine per minute at pH 6.5 and 37° C., Sigma Chem. Co.). The 
acrylamide solution was then degassed for 5 minutes using a cold finger probe 
vacuum pump. N,N,N,N’-Tetramethyl-ethylenediamine (TEMED)(105 ul) and 
ammonium persulfate (2.45 mg) were gently added into the degassed acrylamide/ 
enzyme solution, and the solution transferred into electrophoresis gel tubes (120 
mm X 15 mm) using a Pasteur pipette. Distilled water was carefully applied to
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the top of the gel solutions to fill the gel tube prior to polymerization. During 
the polymerization process the tubes were held in a vertical position in the 
electrophoresis unit with the bottom of each tube tightly covered with a piece of 
parafilm. Gel polymerization was complete in approximately 30 to 50 minutes 
with a clear boundary zone evident between the gel and water overlay. The 
upper and lower chambers of the electrophoresis unit were filled with cold 
electrode buffer (0.05M Tris, 0.005M glycine, pH 8.3) and the water overlay in 
each tube also displaced with buffer. The samples (50 ul), which were mixed with 
sucrose and tracking dye (0.4% bromophenol blue) with protein concentrations of 
2 mg/ml (approximately 100 ug/50 «l/gel), were then applied to the top of gels 
using a PYREX disposable microsampling pipette. The electrophoresis unit was 
placed in the cold room and an initial constant current of 1 mAmp/gel was 
applied until the tracking dye entered the gels. The constant current was then 
increased to 3 mAmp/gel for the whole term of electrophoresis. The power 
source used was a Buchler 3-1500 constant power supply pack. The separation of 
protein samples in the gel occurred from cathode to anode. At the end of the 
run, 3 to 4 hours, each gel column was removed from the electrophoresis tube by 
rimming the tube gently with water using a syringe and cut off at the position of 
the tracking dye. These gels were then transferred into test tubes of the enzyme 
activity staining solution which contained different peptide substrates.
The staining solution was prepared by dissolving 23 mg nitro blue tetrazolium 
(NBT) (Sigma Chem. Co.) and 2.3 mg phenazine methylsulfate (PMS) in 140 ml
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Tris-HCl buffer (0.1M, pH 7.4). The staining solution (10 ml) was transferred to 
individual test tubes (18 X 150 mm) and 1 mg of each peptide tested was 
dissolved in separate tubes to constitute the "staining solution". Individual gels 
were then incubated in this solution overnight in the dark at room temperature. 
Peptidohydrolytic enzyme activity towards a given peptide was detected by the 
appearance of dark blue bands on the gels. The distances of these bands were 
measured from the top of the gels and their relative mobilities (Rm) calculated. 
Rm, refers to the mobility of the peptidase of interest measured with reference to 
the mobility of the tracking dye where:
distance migrated by peptidase
R m =
distance migrated by tracking dye
SYNTHESIS OF BETA-ALANYL-MELPHALAN (BAM). Incorporation of beta- 
alanine and melphalan (Figure 1) was performed using traditional small peptide 
synthesis procedures (Stewart and Yong, 1984) to get the dipeptide beta-alanyl- 
melphalan (figure 2). N-tert-butoxycarbonyl-beta-alanine (BOC-beta-alanine, 
10.589 g; 56 mmoles), dissolved in 80 ml methylene chloride, was added to a 
solution of 5.768 g (28 mmoles) dicyclohexyl-carbodimide (DCCD), which is a 
coupling reagent, dissolved in 240 ml methylene chloride. BOC-beta-alanine is an 
amino protected derivative of beta-alanine. DCCD is a coupling reagent which 
couples a partially protected amino acid or peptide with a free carboxyl group to 
a second carboxyl group protected amino acid or peptide containing a free amino 
group. The resulting solution was stirred at room temperature for 10 minutes
29
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1. Structure of melphalan.
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Figure 2. Structure of beta-alanyl-melphalan.
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and then cooled to 4° C and held for 10 minutes. The formed precipitate was 
removed by filtration and washed with two 80 ml methylene chloride washes.
The washes and the filtrate containing BOC-beta-alanine anhydride were 
combined. Melphalan (4.270 g, 14 mmoles) was slowly added with stirring to 
dimethylformamide (1120 ml). To this solution, after stirring 15 minutes, the 
methylene chloride solution of BOC-beta-alanine anhydride was slowly added. 
After complete addition of the BOC-beta-alanine anhydride, one ml of 
diisopropylethylamine was added and the stirring continued for 4 hours at room 
temperature. The reaction was monitored for ninhydrin positive material. All 
ninhydrin tests proved negative which indicated complete acylation of the amino 
component of melphalan.
The resulting yellow solution was evaporated under vacuum yielding a thick 
yellow oil. The oil was dissolved in toluene and any white insoluble material 
(primarily dicyclohexylurea) was filtered off. The insoluble material was washed 
several times with toluene and the washes were combined with the soluble 
filtrate. The solution was evaporated under vacuum again, yielding a yellow oil. 
The oil was dissolved in ethyl ether and dried under vacuum, leaving an off-white 
solid. This material, BOC-beta-alanyl-melphalan (3.86 g, 58% yield), was 
homogenous by high-performance liquid chromatography (HPLC). This form of 
the dipeptide was most stable for storage and was stored at -20° C. HPLC 
analysis involved use of a Waters’ HPLC system. The columm was a  Vydac (0.4 
X 25 cm)(Waters, MA) and the absorbance detector was set to 210 nm. The
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gradient mobile phase was 0.15 % trifluoroacetic acid in water (solvent A) and 
0.15% trifluoroacetic acid in acetonitrile (solvent B). The gradient mobile phase 
was run at 1 ml/minute of 90% solvent A and 10% solvent B to 50% solvent A 
and 50% solvent B over a 20 minute interval followed by a hold at 50% solvent 
A and 50% solvent B for 5 minutes, then returning to 90% solvent A and 10% 
solvent B over a final interval of 5 minutes.
Prior to utilization in toxicity or chemotherapeutic studies, sufficient 
BOC-beta-alanyl-melphalan was converted to the dipeptide-HCl salt for usage 
over a 1 or 2 month period. For deblocking, the BOC-beta-alanyl-melphalan (1 
mg) was dissolved in 250 ml trifluoroacetic acid (removes BOC group in an 
acidolysis reaction) and reacted at room temperature for 20 minutes. After 
evaporation under minimal vacuum, the resulting yellow-brown oil was 
ninhydrin-positive, and homogenous by HPLC. The oil was treated with a 
three-fold molar excess of 2N HC1 with stirring at room temperature for 10 
minutes. After evaporating the solution under vacuum, the resulting solid was 
also a yellow-brown oil. This compound was ninhydrin positive. HPLC analysis 
indicated this compound to be approximately 85% pure, containing two 
decomposition products comprising 6% and 9% , respectively, of the total "peak 
areas".
CHEMICAL STABILITY OF MELPHALAN AND BETA-ALANYL-MELPHALAN.
Melphalan was dissolved at a concentration of 3.052 mg/ml (0.01 M) in distilled
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water and beta-alanyl-melphalan was dissolved at a concentration of 4.13 mg/ml 
(0.01 M) in distilled water. Solutions of melphalan were made fresh and stored 
on ice prior to use. Degradation was investigated at different temperatures (0° C 
and 37° C) in water, bovine serum albumin solutions (10% and 30% in distilled 
water), and in NCTC-135 culture medium supplemented with 10% fetal bovine 
serum. In experiments on the degradation of melphalan in different solutions, 1 
ml of melphalan solution was added to 4 ml of incubation medium (i.e. BSA 
solution, etc.). At timed intervals, 0.5 ml samples were taken and added to 1 ml 
of methanol. These mixtures were centrifuged in an Eppendorf Centrifuge model 
5412 for 3 minutes at 12,000 rpm. The supernatants were filtered through 
ACRODISC CR disposable syringe filters (0.2 micron), and 10 ul of filtrate used 
for HPLC analysis. HPLC involved use of an ISCO (ISCO, Inc. Lincoln, NE, 
U.S.A) ternary HPLC system incorporating an ISCO Model 2360 gradient 
programmer, an ISCO Model 2350 pump and sample injection valve, and an 
ISCO V4 absorbance detector set to 254 nm (the measured Lamda max of 
melphalan in water is 260nm). Chromatograms were recorded on an AT Turbo 
computer using Isco ChemResearch computer software for data collection. The 
column was a C18 (Octadecyl) 5 um particle size, 250 X 4.5 mm, from IBM 
Instruments, Inc..
The mobile phase was 80% H20  and 20% methanol for melphalan 
separation. The mobile phase was 60% H20  and 40% methanol for 
beta-alanyl-melphalan (BAM) separation. All materials and reagents were of
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HPLC grade and were filtered through a 0.8 um Millipore filter (Millipore, 
Bedford, MA, U.S.A.) prior to use. The flow rate of the mobile phase was 2 
ml/minute.
ENZYME ASSAY. Leucine aminopeptidase assays were performed on the 
extracellular and intracellular extracts of mouse Ehrlich ascites tumor cells. The 
extracellular and intracellular extracts were prepared using the procedure 
mentioned earlier in the section titled Cell Extract Preparation (page 26). The 
cell extract (2 ml) was added to 10 ml of substrate solution (0.2, 0.4, 0.8, 1.2, 1.6, 
2.0, 4.0 mM L-leucine-p-nitroanilide in 4 mM H 2S 0 4) and 10 ml Tris-HCl buffer 
(200 mM Tris, pH 7.4) with 2 ml melphalan (in Tris-Hcl buffer; 2.5 mg/ml) or 2 
ml Tris-HCl buffer as control. This extract/substrate (total 24 ml) mixture was 
incubated in a 37° C water bath. The aliquots (3 ml) were taken out at 0, 5, 10, 
20, 30, and 60 minutes. Ice-cold distilled water (0.5 ml) was added into this 3 ml 
aliquot to stop the reaction and absorbance was measured at 405 nm in a 
Beckman Model 25 Spectrophotometer (BECKMAN, Irvine, CA, U.S.A.). 
Triplicate samples were taken for each assay.
ANALYSIS OF MELPHALAN AND BETA-ALANYL-MELPHALAN (BAM) 
TOXICITY IN CELL CULTURE. For in vitro toxicity assays, mouse Ehrlich 
ascites tumor cells (Tsay strain), mouse liver cells, and mouse 3T3 embryonic 
cells (approximately 100,000 cells) were seeded into T-25 tissue culture flasks 
containing 5 ml of the appropriate culture medium. The culture medium was
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routinely changed twice a week. The cell cultures were incubated at 37° C for 
two days in a humidified C 0 2 incubator. The incubation medium was then 
changed for fresh medium supplemented with the drug being tested. The cultures 
were incubated an additional 24 hours and were then harvested by trypsinization 
and stained using tiypan blue dye exclusion (0.4% trypan blue in Dulbecco’s 
phosphate buffered saline). The cells were counted in a  hemocytometer where 
cells staining blue were considered metabolically "dead" and their number, added 
to the number of "clear" cells (i.e. living cells), equaled total cell number. The 
"dead" cell number was divided by the total cell number to get the % of "dead" 
cells which was then converted to log10. Each assay was done in triplicate culture 
flasks and 3 separate experiments.
For the cell survival study, mouse Ehrlich ascites tumor cells, mouse liver 
cells, and mouse 3T3 embryonic cells were seeded into T-75 tissue culture flasks 
with 15 ml appropriate culture medium. After 48 hours, the culture medium was 
changed for fresh medium supplemented with the drug being tested. After 2 
hours incubation, the cells were harvested and reseeded into T-25 tissue culture 
flasks at a density of 100,000 cells per flask. To get the total cell number, the 
cells were harvested and counted at regular timed intervals. Total cell numbers 
from triplicate assay flasks were averaged and plotted versus time on semi-log 
paper to determine survival curves.
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MORPHOLOGICAL STUDY DURING MELPHALAN AND BETA-ALANYL- 
MELPHALAN (BAM) TREATMENT. Only mouse Ehrlich ascites tumor cells 
and mouse liver cells were used in this study. Light microscopy, scanning (SEM), 
and transmission (TEM) electron microscopy were used for examination of the 
morphology of each cell line which was treated with anticancer drugs. For light 
microscopic and transmission electron microscopic study, cells were seeded into 
T-75 tissue culture flasks and incubated in a humidified C 0 2 incubator at 37° C. 
Cells in the exponential growth phase were used for these experiments and were 
incubated in medium with the drug being tested for 2 hours. Cells were 
trypsinized and pelleted using a  IEC table-top centrifuge (Internation Equipment 
Co., Needham Hights, MA, U.S.A.) at 2,000 rpm for 5 minutes. After the 
supernatant was removed, the cell pellets were fixed (2% glutaraldehyde in 0.1 M 
sodium cacodylate buffer, pH 7.4, for 1 hour at room temperature) and washed 
three times (10 minutes for each wash) with 0.1 M sodium cacodylate buffer. 
After secondary fixation (1% 0 s 0 4 in 0.1 M sodium cacodylate buffer, pH 7.4 for 
90 minutes at 4° C), the cell pellet was rinsed again three times in buffer and 
then dehydrated in a  graded alcohol series (30%, 50%, 70%, 95% and 100%), 
transferred to acetone, and embedded in POLYBED (Polysciences) mixture. 
Sections were cut with a LKB III ultramicrotome. Thick sections were stained 
with Richardson stain for light microscopic examination. Thin sections were 
stained with 2% uranyl acetate and 0.4% lead citrate, and viewed with a Hitachi 
H-U 11B transmission electron microscope (Hitachi, Ltd., Tokyo, Japan).
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For the scanning electron microscopic study, cells were grown on a piece of 
tissue culture cover slip (THERMANOX; Nunc, Inc., Naperville, IL, U.S.A.) in a 
Petri dish. Cells attached on the cover slip were prepared for SEM following the 
same fixation and dehydration procedure as described for the TEM studies. The 
cover slips were dried using a DCP-1 critical point dryer (Enton Accum, Inc., 
Cherry Hill, NJ, U.S.A.), mounted on stubs, and coated with gold/palladium using 
a Polaron E5200 Sputter Coater (Polaron Equipment Ltd., Cambridge, MA, 
U.S.A.). Cells were examined using a Cambridge Stereoscan 100 SEM 
(Deerfield, IL, U.S.A.).
ANALYSIS OF IN VTVO CHEMOTHERAPY. For the chemotherapy assays, 
mouse Ehrlich ascites tumor cells were harvested fresh from the abdominal cavity 
of a mouse into hypotonic buffer (8.0 g NaCl, 0.2 g KC1, 1.15 g NaJHPO,,, 0.2 g 
KH2P 0 4, 0.1 g MgCl2 in 1 liter glass distilled water, pH 7.4). The cells were 
washed with hypotonic buffer until the tumor cells were free of red blood cells 
and lymphocytes and then the tumor cells were transferred to DPBS and injected 
into the abdominal cavity of mice (approximately one million tumor cells per 
mouse). After 24 hours, the drug being tested was injected intraperitoneally at 
the desired concentration. Control mice having been injected with tumor cells 
received a sham injection of the solvent used to inject the drugs. Since all "drugs" 
tested in this study were soluble in DPBS, this solvent was utilized in all assays. 
Additional controls consisted of mice receiving a sham injection of DPBS, i.e. no 
tumor cells and the same drug treatment as the mice receiving the tumor cells.
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The mice were weighed daily and their water and food consumption monitored. 
The survival day after injection of each mouse in the assay was recorded. The 
T /C  ratio was the calculation of the average survival day of mice in a treatment 
group divided by the average survival day of mice in a control group.
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RESULTS
I. Basic Morphology of Mouse Ehrlich Ascites Tumor Cell Line, Mouse Liver 
Cell Line and Mouse 3T3 Embiyonic Cell Line:
The objective of this study was to illustrate the fundamental morphological 
and growth characteristics of the three cell lines grown in cell culture.
A monolayer cell culture of round (80%) and bipolar-shaped (spindle shape) 
cells (20%) is shown (Figure 3). Many doublet-cells are shown and two nuclei 
are seen in some spindle-shaped cells. Both round and spindle-shaped cells 
demonstrated vacuoles and sparse granularity of the cytoplasm is usually 
perinuclear in location. Nuclei typically appeared as round or oval in shape.
Mouse liver cells also demonstrated two types of cell morphology in 
monolayer culture (Figure 4). The majority of mouse liver cells were round 
(90%) with a few spindle-shaped cells demonstrated (10%). Cells appeared to 
contain a single round nucleus and granulated cytoplasm.
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Figure 3. Photomicrograph of mouse Ehrlich ascites tumor cells grown in 
monolayer cell culture. Photograph was taken through an inverted 
microscope (400X).
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Mouse 3T3 embryonic cells typically grew as flattened spindle-shaped cells in 
monolayer cell cultures (Figure 5) exhibiting a "pavement-like" growth pattern 
and cytoplasmic vacuolization. Cells contained single round nuclei and 
granulated cytoplasm.
II. Growth Curves and Population Doubling Time (TD):
The growth characteristics of mouse Ehrlich ascites tumor cells, mouse liver 
cells and mouse 3T3 embryonic cells are shown in Figures 6, 7, and 8. The 
mouse Ehrlich ascites tumor cells were initially seeded from an exponential 
growth cell culture at 2 X 10s cells per 35 nun tissue culture Petri dish (Figure 
6). There was no lag phase before the cell number started to increase. After 72 
hours, the cells depleted the medium of the nutrients essential for growth and 
entered a plateau or stationary phase of growth. The mouse Ehrlich ascites 
tumor cells had a saturation density of 3.2 X 106 cells/35 mm petri dish and a TD 
value of 18 hours.
The growth curve of mouse liver cells is shown in Figure 7. The mouse liver 
cells were also seeded from a exponential growth cell culture at an initial cell 
number of 1.5 X 10s cells per 35 mm tissue culture Petri dish. The mouse liver 
cells had a TD of 29 hours and exhibited no lag phase. The cells had a saturation 
density of 9 X 105 cells/35 mm petri dish after 90 hours.
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Figure 5. Photomicrograph of mouse 3T3 embryonic cells grown in monolayer 
cell culture. Photograph was taken through an inverted microscope 
(400X).
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Figure 6. Growth curve of mouse Ehrlich ascites tumor cells. Mouse Ehrlich 
ascites tumor cells (approximately 200,000 cells) were seeded into 35 mm 
tissue culture petri dishes containing 5 ml NCTC-135 medium 
supplemented with 10% fetal bovine serum. The cell numbers were 
counted twice a day for 4 days, using a hemocytometer. Cell population 
doubling time (TD) was calculated from the linear phase of the growth 
curve. Each data point represents an average of 3 replicate values.
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Figure 7. Growth curve of mouse liver cells. Mouse liver cells (approximately 
100,000 cells) were seeded into 35 mm tissue culture petri dishes 
containing 5 ml NCTC-135 medium supplemented with 10% horse serum. 
The cell numbers were counted twice a day for 6 days, using a 
hemocytometer. Cell population doubling time (T„) was calculated from 
the linear phase of the growth curve. Each data point represents 3 
replicate values.
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Figure 8 shows the growth curve of mouse 3T3 embryonic cells. The cells 
were initially seeded at 1 X 10s cells per 35 mm tissue culture petri dish from an 
exponential growth cell culture. The population doubling time (TD) of mouse 
3T3 embryonic cells was 25 hours. There was no lag phase. After 72 hours, the 
cells entered a plateau phase where a saturation density of 2.7 X 10s mouse 3T3 
cells/35 mm petri dish was calculated. The results here indicated that there was 
no apparent correlation between the population doubling time of these three cell 
lines and their saturation densities and that the doubling times for the cell lines 
were not dramatically different.
III. Peptidohydrolytic Enzyme Activity Assay:
The objective of this study was to characterize the numbers and kinds of 
peptidohydrolytic enzymes which were associated with the growth of mouse 
Ehrlich ascites tumor cells in the abdominal cavity of mice. Tables 1 and 2 
summarize the results of intracellular and extracellular peptidohydrolytic enzyme 
activities from mouse Ehrlich ascites tumor cells. Proteins in ascites fluids and 
cellular homogenates were separated on the basis of charge using polyacrylamide 
tube gel electrophoresis. The enzyme L-amino acid oxidase (EC 1.4.3.2) was 
polymerized within the gel and catalyzed the oxidation of L-amino acids liberated 
following the hydrolysis of specific peptides by the electrophoretically separated 
peptidohydrolytic enzymes. The L-amino acid oxidase transfers electrons to 
phenazine methosulfate which in turn transfers them to the nitroblue tetrazolium
47
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Figure 8. Growth curve of mouse 3T3 embryonic cells. Mouse 3T3 embryonic 
cells (approximately 100,000 cells) were seeded into 35 mm tissue culture 
petri dishes containing 5 ml Dulbecco’s modified Eagle’s medium 
supplemented with 10% calf serum. The cell numbers were counted twice 
a day for 3 days, using a hemocytometer. Cell population doubling time 
(Td) was calculated from the linear phase of the growth curve. Each data 
point represents an average of 3 replicate values.
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dye. The reduced dye forms an intense blue precipitate, formazan, at the site of 
peptidohydrolase activity (Figures 9 and 10). Using the thirty seven peptides 
listed in Table 1 it was possible to distinguish six electrophoretically distinct 
peptidase activities present in the intracellular extract of mouse Ehrlich ascites 
tumor cells. In addition, the substrate specificities of these separate activities 
have been partially characterized according to their abilities to hydrolyze 
substrate peptides. The peptidohydrolytic activities described in Table 1 are 
referred to as peptidases A, B, C, D, E and F. Their relative activities with 
different substrates and Rro values are indicated in Table 1. Certain peptides, for 
example L-leucyl-L-histidine and glycyl-L-leucyl-L-tyrosine, appeared to be readily 
hydrolyzed by several of these peptidases, such that when they were used as 
substrates a complex pattern of stained activity bands was seen (Figure 9). With 
other peptide substrates, simpler patterns were observed because they are 
hydrolyzed by only one of the peptidases present, i.e. activity against 
L-alanyl-L-tyrosine and glycyl-beta-alanine appeared to be restricted to peptidase 
D and activity against L-leucyl-L-alanine, L-leucyl-glycine and L-histidyl-L-leucine 
was restricted to peptidase C.
Peptidase A, which has a Rm value range from 0.26 to 0.28, hydrolyzed 3 
dipeptides (L-leucyl-L-histidine, L-leucyl-L-tyrosine, L-methionyl-L-histidine). It is 
very active against L-leucyl-L-tyrosine and weaker against L-leucyl-L-histidine and 
L-methionyl-L-histidine. No hydrolysis of any of the tripeptides by peptidase A 
has been observed.
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Figure 9. Peptidohydrolytic enzyme activities of cell extracts of mouse Ehrlich 
ascites tumor cells. Proteins (peptidohydrolases) were separated by 7.5 % 
polyacrylamide tube gel electrophoresis and stained using an in situ activity 
stain as described in the materials and methods. The bands represent the 
activities of peptidohydrolytic enzymes.
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Table 1. Analysis of intracellular peptidohydrolytic enzyme activity using 7.5% 
polyacrylamide gel electrophoresis with in situ staining at pH 7.0. 
Hydrolysis of the peptide is indicated by the presence of bands in the gels 
and shown as -(no hydrolysis), + (very weak hydrolysis), + + (weak 
hydrolysis), + + + (medium hydrolysis), + + + + (strong hydrolysis).
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Peptide Band
Beta-ala-L-ala
A B C D E F
L-ala-L-ala - - + + -
Beta-ala-gly - - - - -
L-ala-phe - + + - - + + + + -
L-ala-L-tyr - - - + + + + -
L-leu-L-ala - - + + - -
L-leu-gly - - + + - -
L-leu-L-his + + + + +
L-leu-L-leu - - + + - -
L-leu-L-phe - - - - -
L-leu-L-tyr + + + - - + + + + -
L-phe-L-leu - - + + - -
L-met-L-his + - - + +
L-met-L-leu - + + - + + -
L-his-L-leu - - + + + -
Gly-beta-ala - - - + -
Gly-DL-met - - - + +
Gly-L-tyr - - - - -
L-ala-L-ala-L-ala - - - - -
L-ala-gly-gly - - - - -
Gly-L-ala-L-leu - - - - -
Gly-gly-gly - - - - -
Gly-gly-L-leu - - - - -
Gly-gly-D-leu - - - - -
Gly-DL-leu-DL-alpha-ala - - - - -
Gly-L-leu-L-tyr - + - + + + +
Gly-L-phe-L-phe - - - - -
Gly-sarcosine - - - - -
L-his-L-gly-gly - - - - -
L-leu-gly-gly - - - - -
L-leu-L-leu-L-leu - - - - -
Tetra-L-ala - - - - -
Tetra-gly - - - - -
Gly-gly-L-tyr-arg - - - - -
Penta-gly - - - - -
Hexa-gly - - - - -
Poly-gly
Rm values corresponding to peptides: 
A: 0.260- 0.280 D: 0.580- 0.600
B: 0.280- 0.300 E: 0.600- 0.620
C: 0.300- 0.320 F: 0.620- 0.640
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Peptidase B, which has a Rm range from 0.28 to 0.30, hydrolyzed three 
dipeptides (L-alanyl-L-phenylalanine, L-leucyl-L-histidine, L-methionyl-L-leucine) 
and one tripeptide (glycyl-L-leucyl-L-tyrosine).
Peptidase C, which has a Rm range from 0.30 to .0.32, shows strong activity 
against a number of the dipeptides listed in Table 1, but not against any of the 
tripeptides tested. Its substrate specificity, however, was very different from that 
of peptidase A, except that it also appeared to be primarily a dipeptidase.
Peptidase D, which had a Rm range from 0.58 to 0.60, was very active against 
L-alanyl-L-tyrosine, L-leucyl-L-tyrosine and the tripeptide glycyl-L-leucyl-L- 
tyrosine. It showed weaker activity against the dipeptides L-alanyl-L-alanine, 
L-leucyl-L-histidine, L-methionyl-L-histidine, glycyl-beta-alanine, and glycyl-DL- 
methione.
Peptidase E, which has a Rm range from 0.60 to 0.62, showed very strong 
activity towards L-alanyl-L-phenylalanine and also had been detected with 
L-leucyl-L-histidine, L-methionyl-L-histidine, L-methionyl-Lleucine, glycyl-D- 
methione and glycyl-Lleucyl-L-tyrosine, but its activity in each case was relatively 
weak.
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Peptidase F had a R m value range from 0.62 to 0.64, and has so far only been 
found to show significant activity against L-phenylalanyl-L-leucine.
Therefore, at the substrate concentrations tested, peptidases A, C and F  can 
be defined as dipeptidases and peptidases B, D, E were able to hydrolyze both 
dipeptides and tripeptides.
Among the eighteen dipeptides tested, only four were resistant to hydrolysis 
by intracellular peptidohydrolytic enzymes. They are beta-alanyl-L-alanine, 
beta-alanyl-L-glycine, L-leucyl-L-phenylalanine and glycyl-L-tyrosine. It is 
suggested therefore that peptides containing an amino terminal beta-amino acid 
i.e. beta-alanyl-glycine, beta-alanyl-L-alanine, are resistant to hydrolysis by 
available intracellular peptidases and thus should make good substrates for the 
study of peptide transport and cancer chemotherapy using peptide-like anticancer 
drugs. Of all tripeptides tested only glycyl-L-leucyl-L-tyrosine was hydrolyzed by 
the sum-total intracellular peptidohydrolytic enzymes, the rest of them were 
shown to be relatively resistant to hydrolysis under the assay conditions employed.
Analysis of extracellular peptidohydrolytic enzyme activity (Figure 10 and 
Table 2) revealed a total of three electrophoretically distinct peptidase activities. 
Peptidase A’, which had a Rm value range from 0.13 to 0.135 hydrolyzed a 
number of dipeptides (Table 2). The peptidase activity varied somewhat from 
substrate to substrate in that it was very active against L-leucyl-L-tyrosine, but less
53
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Figure 10. Peptidohydrolytic enzyme activities in ascites fluid of mouse Ehrlich 
ascites tumor cell bearing mice. Proteins (peptidohydrolases) were 
separated by 7.5 %  polyacrylamide tube gel electrophoresis and stained 
using an in situ activity stain as described in the materials and methods. 
The bands represent the activities of peptidohyrolytic enzymes.
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Table 2. Analysis of extracellular peptidohydrolytic enzyme activity using 7.5% 
polyacrylamide gel electrophoresis with in situ staining at pH 7.0. 
Hydrolysis of the peptide is indicated by the presence of bands in the gels 
and shown as -(no hydrolysis), + (very weak hydrolysis), + + (weak 
hydrolysis), + + + (medium hydrolysis), + + + + (strong hydrolysis),
+ + + + + (very strong hydrolysis).








L-leu-L-ala + + -
L-leu-gly + + -
L-leu-L-leu + + + -













L-leu-gly-gly + + -







R m values corresponding to peptides:
A’: 0.130- 0.135 
B’: 0.140- 0.145 
C’: 0.520- 0.550
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active towards the tripeptides, L-leucyl-glycyl-glycine and L-leucyl-L-leucyl-L- 
leucine (Table 2). Peptidase B’, which had a Rm range from 0.140 to 0.145, 
showed weak activity against I^alanyl-L-phenylalanine and L-alanyl-L-tyrosine.
No hydrolysis of any of the tripeptides was observed. Peptidase C’, which had a 
Rm value range from 0.520 to 0.550, also hydrolyzed two dipeptides, L-alanyl-L- 
tyrosine and glycyl-L-tyrosine, and none of the tripeptides. Both peptidase B’ and 
C’ appear to be primarily dipeptidases.
Among the eleven dipeptides tested, only beta-alanyl-L-alanine and 
beta-alanyl-glycine were resistant to hydrolysis by extracellular peptidohydrolytic 
enzymes. These results support the suggestion that peptides containing an amino 
terminal beta-amino acid are good candidates for use in the design of anticancer 
drugs and of those peptides larger than a dipeptide, only L-leucyl-glycyl-glycine 
and L-leucyl-L-leucyl-L-leucine were hydrolyzed under conditions of this assay by 
the extracellular peptidohydrolytic enzymes.
IV. Synthesis and Purification of Beta-alanyl-melphalan (BAM):
The synthesis of the dipeptide utilized in this study involved the 
condensation of N-tert-butyloxycarbonyl-beta-alanine (BOC-beta-alanine) with the 
bifunctional alkylating agent melphalan. The melphalan and BOC-beta-alanine 
were purchased from Sigma Chemical Company. Analysis of the purity of these 
two reactants by high-performance liquid chromatography (HPLC) (figures 11 and
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Figure 11. High-performance liquid chromatographic (HPLC) analysis of
BOC-beta-alanine. Retention time (RT; in minutes) of materials eluting 
from the Clg column and absorbing at 210 nm.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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12) revealed that they were essentially pure, as determined by absorbance at 210 
nm. The melphalan contained a minor contaminant which eluted early and 
constituted less than 10% of the 210 nm absorbing material (Figure 12).
Following condensation of the reactants, the dipeptide BOC-beta-alanyl- 
melphalan was analyzed for purity and completeness of reaction. The reaction 
was continuously monitored for ninhydrin-positive materials during the course of 
the reaction. HPLC analysis of the final product revealed the presence of a 
minor trace of materials absorbing at 210 nm, and a major peak at the position of 
21.2 min, at which the BOC-beta-alanyl-melphalan eluted and which comprised 
over 96% of the available material eluting from the column (Figure 13). As 
demonstrated in Figure 11, the product was essentially pure, and the major 
portion of the synthetic product was stored frozen (-20° C) in a desiccator. The 
derivitized dipeptide was a white powdery material that could be easily weighed 
and aliquoted. Deblocking the peptide, i.e. conversion of BOC-beta-alanyl- 
melphalan to beta-alanyl-melphalan (BAM), resulted in the conversion of a dry 
powdery material into an oily residue which was difficult to weigh. Consequently, 
only a sufficient quantity of dipeptide was deblocked at any one time to permit 
testing over a period of 1 to 2 months.
Following deblocking, the TFA salt form of beta-alanyl-melphalan (Figure 14) 
was converted to the HC1 salt form prior to analysis and utilization in toxicity 
testing. HPLC analysis of the TFA salt form of beta-alanyl-melphalan revealed a
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Figure 12. High-performance liquid chromatographic (HPLC) analysis of
melphalan. Retention time (RT; in minutes) of materials eluting from the 
CI8 column and absorbing at 210 nm.
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Figure 13. High-performance liquid chromatographic (HPLC) analysis of the 
immediate product of peptide synthesis, BOC-beta-alanyl-melphalan. 
Retention time (RT; in minutes) of materials eluting from the C18 column 
and absorbing at 210 nm.
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Figure 14. High-performance liquid chromatographic (HPLC) analysis of the
TFA salt form of beta-alanyl-melphalan. Retention time (RT; in minutes) 
of materials eluting from the C18 column and absorbing at 210 nm.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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single major peak of 210 nm absorbing eluting at 15.2 min. Analysis of the HC1 
salt form of beta-alanyl-melphalan by HPLC revealed the presence of at least 
three 210 nm absorbing compounds comprising less than 14% of the total 210 nm 
absorbing materials. The absorbance of these "contaminant" peaks in the HC1 
salt form of the beta-alanyl-melphalan indicates that they are the result of the 
generation of the HC1 salt form of beta-alanyl-melphalan from the TFA  salt form 
of beta-alanyl-melphalan. The major peak of 210 nm absorbing materials (beta- 
alanyl-melphalan) eluted at 15.2 min and comprised over 85% of the available 
material eluting from the column (Figure 15). The retention time of beta-alanyl- 
melphalan HC1 was significantly different from the retention times of melphalan 
(13.6 minutes) and BOC-beta-alanine (7.2 minutes).
V. Chemical Stability of Melphalan and Beta-alanyl-melphalan:
Alkylating agents are typically chemically reactive, i.e. unstable, and are thus 
inherently difficult to work with. The main product of hydrolysis is the dihydroxy 
compound, and the intermediate monohydroxy compound also can be found 
(diagram 1). High-performance liquid chromatography (HPLC) was used to 
investigate stability of solutions of melphalan under conditions that pertain to 
analysis of in vitro toxicity and in vivo chemotherapy.
A representative example (melphalan) of the chromatograms produced with 
HPLC used in this work is given in Figure 16. The chromatogram shows a minor
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Figure 15. High-performance liquid chromatographic (HPLC) analysis of the HC1 
salt form of beta-alanyl-melphalan. Retention time (RT; in minutes) of 
materials eluting from the C18 column and absorbing at 210 nm.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Diagram 1:
Spontaneous degradation of meiphalan 
in aqueous solution.
Meiphalan (4-bis-(2-chloroethyl) am ino-L-phenylalanine)
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NH.
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Figure 16. Chromatogram from the high-performance liquid chromatograph
(HPLC) showing peaks of freshly-made meiphalan (3 mg/ml) dissolved in 
distilled water. Absorbance monitored at 254 nm. The injection point is 
indicated by a vertical line. Two products were present, one eluting at 
2.25 minutes and the other, at 8.81 minutes. Peak 2 represents meiphalan 
and peak 1 represents the hydrolysis product of meiphalan (dihydroxy 
meiphalan). The first peak constitutes 7% of total material which 
indicates the purity of meiphalan is 93%.










































peak (peak 1) at 2.25 minutes and a major peak (peak 2) at 8.81 minutes. The 
major peak represents meiphalan whereas the minor peak represents the 
breakdown products of meiphalan, either monohydroxy meiphalan or dihydroxy 
meiphalan. It is unknown whether the monohydroxy or dihydroxy form of 
meiphalan is preferentially formed during chemical decomposition of meiphalan. 
In order to identify peak 1 in the HPLC chromatogram, dihydroxy meiphalan was 
obtained via a complete hydrolysis of meiphalan by incubation in glass distilled 
H 20  at 60° C in a water bath for 2 hours. HPLC analysis of this incubation 
solution revealed only one major peak with a retention time of 2.17 minutes 
(Figure 17). The results indicated that the first peak in the chromatographic 
profile in Figure 16 is dihydroxy meiphalan. These results further indicated that 
this type of analysis is suitable for study of the stability of meiphalan, as the peak 
of the only known degradation product was well separated from the peak of its 
parent drug meiphalan.
The hydrolysis rate of meiphalan to dihydroxy meiphalan in distilled water at 
different temperatures was studied. Meiphalan (3 mg/ml) was dissolved in 
distilled water and incubated at 0° C and 37° C. Samples were taken at 
designated times and analyzed by HPLC. As shown in Table 3, the percentage of 
peak area of meiphalan (peak 2) decreases from 92.45% (9.088 nmole) at zero 
time to 42.33% (4.161 nmole) after 120 minutes of incubation at 37° C. In 
contrast, peak 1 (dihydroxy meiphalan) exhibited an increase in the percentage of 
peak area from 7.54% (0.741 nmole) at zero time to 57.67% (5.668 nmole) after
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Figure 17. Chromatogram from the high-performance liquid chromatography 
(HPLC) of the hydrolysis product of meiphalan (dihydroxy meiphalan). 
Dihydroxy meiphalan was obtained via a complete hydrolysis of meiphalan 
(3 mg/ml) in distilled water at 60° C in a water bath for 2 hours. Only 
one product was present with a retention time of 2.17 minutes.
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Table 3. High-performance liquid chromatography (HPLC) Analysis of
Meiphalan in distilled water at 0° C.
Time Peak # RT %  of Peak Area Concentration
0 1 2.35 6 .92 0.680
2 8.65 93.08 9.150
60 1 2.54 6.36 0.625
2 8.79 93.64 9.205
120 1 2.19 6.89 0.677
2 8.21 93.11 9.153
a. Peak number corresponds to appearance of 254 nm absorbance material from 
C,g column.
b. RT = Retention Time in minutes.
c. % of Peak Area is obtained by adding the peak areas of 1 and 2, and then 
dividing each peak area by the total area.
d. concentration is obtained from a standard curve of meiphalan correlating peak 
area of peak 2 with nmole of meiphalan analyzed.
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120 minutes incubation at 37° C. These results indicated that 45% of the 
meiphalan had broken down to dihydroxy meiphalan after 120 minutes incubation 
at 37° C. Table 4 presents data from the HPLC analysis of meiphalan in distilled 
water at 0° C. The results revealed that the percentage of the peak area of peak 
2 (meiphalan) decreased from 93.08% (9.150 nmole) at zero time and to 93.11% 
(9.153 nmole) after 120 minutes incubation at 0° C. The percentage of peak 1 
(dihydroxy meiphalan) decreased from 6.92% (0.680 nmole) at zero time to
6.89% (0.677 nmole) after 120 minutes incubation at 0° C. The results indicated 
that meiphalan did not break down over the 120 minutes of incubation at 0° C. 
The hydrolysis of meiphalan in distilled water as a function of incubation time at 
0° C and 37° C is shown graphically in Figures 18 and 19, respectively. When 
meiphalan solution was incubated on ice, the results revealed that there was no 
significant change in peak area of either peak 1 or 2 over an incubation interval 
of 120 minutes (Figure 18). The degradation rate of meiphalan at 37° C (Figure 
19) is much faster than at 0° C. These results indicated that meiphalan was 
degraded to hydroxy meiphalan as a linear function of time. A direct comparison 
of hydrolysis of meiphalan in distilled water at 0° C and 37° C is shown in Figure 
20. A rapid degradation is shown with a rate constant of 0.433 nmole of 
meiphalan degradation per minute at 37° C. A very slow degradation rate was 
observed with a rate constant of 0.00025 nmole of meiphalan degradation per 
minute at 0° C. An Analysis of Covariance (ANCOVA), examining the 
significance of the difference of slope between 37° C and 0° C, was statistically 
significant (p < 0.005). This shows that the breakdown process of meiphalan was
69
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Table 4. High-performance liquid chromatography (HPLC) Analysis of
Meiphalan in distilled water at 37° C.
Time Peak # RT % of Peak Area Concentration
0 1 2.49 7.54 0.741
2 9.01 92.45 9.088
30 1 2.32 13.73 1.350
2 8.55 86.27 8.480
60 1 2.39 29.82 2.931
2 8.44 70.18 6.899
120 1 2.23 57.67 5.668
2 8.19 42.33 4.161
a. Peak number corresponds to appearance of 254 nm absorbance material from 
C18 column.
b. RT = Retention Time in minutes.
c. % of Peak Area is obtained by adding the peak areas of 1 and 2, and then 
dividing each peak area by the total area.
d. concentration is obtained from a standard curve of meiphalan correlating peak 
area of peak 2 with nmole of meiphalan analyzed.
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Figure 18. Degradation of meiphalan (3 mg/ml) in distilled water at 0° C.
Samples were taken at designated times and analyzed by high-performance 
liquid chromatography (HPLC). Peak 1 represents the hydrolysis product 
of meiphalan whereas peak 2 represents meiphalan. Peak areas integrated 
using the Isco ChemResearch computer program were converted to the 
concentrations of meiphalan (in nmole) using a standard curve of 
meiphalan concentrations versus peak areas.
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Figure 19. Degradation of meiphalan (3 mg/ml) in distilled water at 37° C.
Samples were taken at designated times and analyzed by high-performance 
liquid chromatography (HPLC). Peak 1 represents the hydrolysis product 
of meiphalan whereas peak 2 represents meiphalan. Peak areas integrated 
using the Isco ChemResearch computer program and then converted to the 
concentration of meiphalan (in nmole) using a standard curve of 
meiphalan concentrations versus peak areas.
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Figure 20. Comparison of degradation of meiphalan (3 mg/ml) in distilled water 
at 0° C and 37° C. Samples were taken at designated times and analyzed 
by high-performance liquid chromatography (HPLC). Peak areas 
integrated using the Isco ChemResearch computer program were 
converted to the concentration of meiphalan (in nmole) using a standard 
curve of meiphalan concentration versus peak area.
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slower at the lower temperature.
The stability of meiphalan was also studied under a variety of aqueous 
conditions. Meiphalan was added to various concentrations of bovine serum 
albumin and incubated at 37° C. The hydrolysis of meiphalan in water solutions 
of bovine serum albumin at 37° C as a function of incubation time is shown in 
Figure 21. Hydrolysis rate constants of meiphalan in BSA solution are 0.313 
nmole per minute (10% BSA) and 0.227 nmole per minute (30% BSA). The 
results revealed that the hydrolysis rate of meiphalan was retarded approximately 
25% and 48% by 10% and 30% BSA, respectively. ANCOVA analysis showed 
that there was no significant difference between meiphalan degradation in 0% 
BSA and 10% BSA, but there was a significant difference between meiphalan 
degradation in 0% BSA and 30% BSA (p < 0.005). When meiphalan 
degradation rates in 10% BSA and 30% BSA were compared, significant 
differences were also found (p < 0.005). The results indicated that inclusion of 
BSA, and perhaps other proteins, may stabilize meiphalan, especially at higher 
concentrations of BSA.
Having determined the stability of meiphalan before it was put into an in 
vitro assay, experiments were performed to determine its stability under typical in 
vitro assay conditions. Meiphalan was added to NCTC-135 cell culture medium 
supplemented with 10% fetal bovine serum (FBS) and incubated at 37° C. The 
degradation of meiphalan in FBS supplemented NCTC-135 medium at 37° C as a
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Figure 21. Comparison of degradation rates of meiphalan (3 mg/ml) in varied 
concentrations (0%, 10%, 30%, w/v) of bovine serum albumin (BSA). 
Samples were taken at designated times and analyzed by high-performance 
liquid chromatography (HPLC). Peak areas integrated using the Isco 
ChemResearch computer program were converted to the concentration of 
meiphalan (in nmole) using a standard curve of meiphalan concentration 
versus peak area.
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Figure 22. Degradation of meiphalan (3 mg/ml) in NCTC-135 medium
supplemented with 10% fetal bovine serum at 37°C. Samples were taken 
at designated times and analyzed by high-performance liquid 
chromatography (HPLC). Peak areas integrated using the Isco 
ChemResearch computer program were converted to the concentrations of 
meiphalan using a standard curve of meiphalan concentration versus peak 
area. Peak 1 represents the hydrolysis product of meiphalan and peak 2 
represents meiphalan.
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function of incubation time is shown in Figure 22. The hydrolysis rate of 
meiphalan in FBS supplemented NCTC-135 medium is 0.262 nmole per minute. 
ANCOVA analysis revealed there is no significant difference between meiphalan 
degradation in FBS supplemented NCTC-135 medium and distilled water, or 10% 
BSA, or 30% BSA. However, the results still indicated that FBS supplemented 
NCTC-135 medium slowed down the hydrolysis process by 37% when compare to 
the rate of hydrolysis in distilled water.
No significant change in meiphalan concentration was seen when 3 mg/ml 
meiphalan was stored at 0° C for 3 weeks (9.25 nmole to 8.20 nmole). However, 
from the results in Table 5 a half-life of 105.21 minutes was calculated for 
meiphalan incubated at 37° C. The calculated half-life of meiphalan was 176.72 
minutes and 142.64 minutes when meiphalan was incubated at 37° C in aqueous 
solutions of 30% and 10% BSA (w:v) respectively. A half-life of 166.82 minutes 
was calculated for meiphalan incubation in NCTC-135 medium supplemented 
with 10% FBS. There is essentially no difference in decomposition of meiphalan 
in 30% BSA, 10% BSA and supplemented NCTC-135 medium, however, the 
results showed that there was a significant difference between distilled water and 
30% BSA at 37° C (p < 0.005). There was also a significant difference between 
10% BSA and 30% BSA at 37°C (p < 0.005). Based on the available results to 
may be suggested that meiphalan can be stored at 0° C for a period of 3 weeks 
without significant decomposition.
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Table 5. Stability of meiphalan in various solutions as analyzed by 
high-performance liquid chromatography (HPLC).
Condition Half-life (minute)
Distilled water, 0° C Below Detection Limit
Distilled water, 37° C 105.21
Bovine serum albumin (10%), 37° C 142.64
Bovine serum albumin (30%), 37° C 176.72
NCTC-135 medium with 
10% fetal bovine serum, 37° C
166.82
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Studies on the stability of beta-alanyl-melphalan has been restricted, due to a 
limited supply of beta-alanyl-melphalan. A typical HPLC chromatograph of 
beta-alanyl-melphalan is shown in Figure 23. One major peak (peak 2) was seen 
at about 13.3 minutes and one minor peak (peak 1) was seen at about 7.4 
minutes. According to the study of meiphalan hydrolysis, the major peak 
presumably represents beta-alanyl-melphalan and the minor peak represents 
hydrolysis product, i.e. beta-alanyl-dihydroxy-melphalan.
Freshly prepared beta-alanyl-melphalan (4.13 mg/ml) was dissolved in 
distilled water and incubated at 37° C in a water bath. As shown in table 6, the 
percentage of peak area of beta-alanyl-melphalan decreased from 93.35% (6.254 
nmole) at zero time to 84.92% (5.690 nmole) after 120 minutes incubation at 37° 
C. The percentage of peak area of peak 1 (dihydroxy form of beta-alanyl- 
melphalan) increased from 6.65% (0.446 nmole) at zero time to 15.08% (1.010 
nmole) after 120 minutes incubation. The hydrolysis of beta-alanyl-melphalan in 
distilled water at 37° C as a function of time is shown in Figure 24. A 
degradation rate of 0.0705 nmole per minute was calculated, which is much 
slower than the calculated hydrolysis rate of meiphalan at 37° C (0.433 nmole per 
minute). The calculated half-life of beta-alanyl-melphalan in distilled water at 37° 
C was 607.71 minutes, which was about 5.6 times longer than the half-life of 
meiphalan incubated in distilled water at 37° C.
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Figure 23. Typical high-performance liquid chromatography (HPLC) tracing 
showing peaks of freshly-made beta-alanyl-melphalan (4.13 mg/ml) 
dissolved in distilled water. Absorbance was monitored at 254 nm. The 
injection point is indicated by a vertical line. One minor peak eluted at 
7.4 minutes and one major peak eluted at 13.3 minutes. Peak 1 
presumably represents the hydrolysis product of beta-alanyl-melphalan 
(beta-alanyl-dihydroxy-melphalan) and peak 2 represents beta-alanyl- 
melphalan.










inoCDoo oo» oCO o T“
A1ISN31NI 3ALLVT3U






Table 6. High-performance liquid chromatography (HPLC) analysis of beta- 
alanyl-melphalan incubated in distilled water at 37° C for the indicated time 
intervals.
Time Peak # RT % of Peak Area Concentration
0 1 6.8 6.65 0.446
2 12.8 93.35 6.254
30 1 7.2 9.96 0.667
2 13.2 90.04 6.033
60 1 7.9 10.90 0.730
2 13.8 89.10 5.970
90 1 7.6 14.26 0.955
2 13.5 85.74 5.745
120 1 7.8 15.08 1.010
2 13.9 84.92 5.690
a. Peak number corresponds to appearance of 254 nm absorbance material from 
C18 colum.
b. RT = Retention Time in minutes.
c. % of Peak Area is obtained by adding the peak areas of 1 and 2, and then 
dividing each peak area by the total area.
d. Concentration is obtained from a standard curve of beta-alanyl-melphalan 
where peak area was correlated with nmole of peptide analyzed.
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Figure 24. Degradation of beta-alanyl-melphalan (4.13 mg/ml) in distilled water 
at 37°C. Samples were taken at designated times and analyzed by 
high-performance liquid chromatography (HPLC). Peak 1 represents the 
hydrolysis product of beta-alanyl-melphalan whereas peak 2 represents 
beta-alanyl-melphalan. Peak areas were integrated using the Isco 
ChemResearch computer program were converted to concentrations of 
beta-alanyl-melphalan using a standard curve of beta-alanyl-melphalan 
concentration versus peak area.
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When beta-alanyl-melphalan was stored at 0° C for three weeks only 6.5% 
degradation was observed, i.e. from 6.33 nmole to 5.92 nmole. These limited 
results indicated that the dipeptide beta-alanyl-melphalan was more stable than 
melphalan in distilled water.
VI. Reactivity of Melphalan and Beta-alanyl-melphalan Toward
Peptidohydrolytic enzymes:
Although the reported mechanism of melphalan toxicity toward cells involves 
its reactivity toward guanine residues in DNA (Hansson, et al., 1987), the 
bifunctional alkylating group at the para-position on the aromatic side group of 
phenylalanine could also be reactive toward proteins, i.e. through primary amine 
reactivity. In order to test this possibility, we assayed the ability of melphalan to 
react with and inhibit peptidohydrolytic enzymes.
Rather than attempting to test a large number of peptidohydrolytic enzymes, 
a typical peptidohydrolytic enzyme, L-leucine aminopeptidase, was chosen for 
analysis. L-leucine aminopeptidase digests L-leucine-p-nitroanilide into L-leucine 
and p-nitroaniline, the later of which is a yellow compound that can be detected 
by use of a spectrophotometer set at 405 nm. Enzyme activity assays were 
performed by incubation of dialyzed intracellular extract or dialyzed ascites fluid 
with L-leucine-p-nitroanilide in the presence and absence of melphalan. 
Intracellular extract represents the component which is inside the mouse Ehrlich
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ascites tumor cells and ascites fluid represents the extracellular component which 
is secreted from Ehrlich ascites tumor cells and the mouse.
The kinetic properties of L-leucine aminopeptidase associated with the 
intracellular extract of mouse Ehrlich ascites tumor cells and ascites fluid from 
mouse Ehrlich ascites tumor cell bearing mice were evaluated at several 
concentrations of substrate (L-leucine-p-nitroaniline). L-leucine aminopeptidase 
activity in intracellular extracts from mouse Ehrlich ascites tumor cells exhibited 
typical Michaelis-Menten saturation kinetics (Figure 25). This l-leucine 
aminopeptidase activity was inhibited by 10 mg melphalan (Figure 25). A 
Lineweaver-Burk plot for inhibition of intracellular extract of mouse Ehrlich 
ascites tumor cells is shown in Figure 26. The effect of melphalan was not 
overcome by increasing the concentration of substrate (l-leucine-p-nitroanilide) 
and thus a decrease in apparent V ^ , was observed, without a change in the 
apparent (Table 7) for intracellular extract in the presence of melphalan (0.16 
nM). The apparent values, from the double-reciprocal plot, were calculated 
to be 0.92 mM for intracellular extract and intracellular extract in the presence of 
melphalan (Table 7). The maximum hydrolytic activities (V ^) were 4.18 and 
3.23 umole/minute/mg protein for intracellular extract and intracellular extract in 
the presence of melphalan, respectively (Table 7). These results indicate that 
melphalan acts as a noncompetitive inhibitor of L-leucine aminopeptidase activity 
present in the intracellular extract of mouse Ehrlich ascites tumor cells.
Therefore, melphalan may bind to either free L-leucine aminopeptidase or the L-
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Figure 25. L-leucine aminopeptidase activity associated with intracellular extract 
of mouse Ehrlich ascites tumor cells in the presence and absence of 
melphalan (0.16 mM). Data are presented as reaction velocity versus 
substrate (l-leucine-p-nitroanilide) concentration.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Figure 26. A double-reciprocal plot (Lineweaver-Burk plot) of L-leucine 
aminopeptidase activity associated with intracellular extract of mouse 
Ehrlich ascites tumor cells in the presence and absence of melphalan (0.16 
mM).
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Table 7. Kinetic constants for L-leucine aminopeptidase activity in the presence 
and absence of melphalan.
K . V* max
Dialyzed ascites fluid 2.08 0.63
Dialyzed ascites fluid 
with melphalan (5 mg)
1.67 0.42
Dialyzed intracellular extract 0.92 4.18
Dialyzed intracellular extract 
with melphalan (5 mg)
0.92 3.23
Measured as hydrolysis of L-leucine-p-nitroanilide. 
Kn, as mM.
Vm„ as umole/minute/mg protein.
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leucine aminopeptidase/L-leucine-p-nitroanilide complex (enzyme/substrate 
complex) or by this, or a similar mechanism, to reduce enzyme activity.
Results from the analysis of L-leucine aminopeptidase activity in dialyzed 
ascites fluid are shown in Figure 27. These results clearly demonstrate that the 
ascites fluid also had the ability to catalyze the hydrolysis of L-leucine-p- 
nitroanilide and that the enzyme activity was inhibited by melphalan. A 
Lineweaver-Burk plot for melphalan inhibition of L-leucine aminopeptidase 
activity in ascites fluid is shown in Figure 28. The kinetic constants of L-leucine 
aminopeptidase activity in ascites fluid were calculated from the double reciprocal 
plot (Figure 28) and the apparent Kn, values were 2.08 mM and 1.67 mM for 
dialyzed ascites fluid and dialyzed ascites fluid in the presence of melphalan, 
respectively (Table 7). The maximum hydrolytic activity (V^,) for dialyzed ascites 
fluid and dialyzed ascites fluid plus melphalan were 0.63 and 0.42 
umole/minute/mg protein, respectively (Table 7). These results indicate that 
melphalan inhibited the L-leucine aminopeptidase activity in ascites fluid in an 
uncompetitive manner. The kinetics of uncompetitive inhibition are characterized 
by changes in both apparent and values in presence of inhibitor. 
Therefore, melphalan may bind to the enzyme/substrate complex or analogous to 
inhibit enzyme activity.
Results describing the inhibition of L-leucine aminopeptidase activity by beta- 
alanyl-melphalan was presented in Figure 29. Due to the limited supply of beta-
88
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Figure 27. L-leucine aminopeptidase activity associated with ascites fluid from
mouse Ehrlich ascites tumor cell bearing mice in the presence and absence 
of melphalan (0.16 mM). Data are presented as reaction velocity versus 
substrate (L-leucine-p-nitroanilide) concentration.
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Figure 28. A double-reciprocal plot (Lineweaver-Burk plot) of L-leucine
aminopeptidase activity associated with ascites fluid from mouse Ehrlich 
ascites tumor cell bearing mice in the presence and absence of melphalan 
(0.16 mM).
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Figure 29. L-leucine aminopeptidase activity associated with intracellular extract 
of Ehrlich ascites tumor cells at the substrate concentration of 2 mM in 
the presence and absence of beta-alanyl-melphalan (0.68 mM). Data are 
presented as a plot of absorbance versus time.
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alanyl-melphalan, the kinetic properties of L-leucine aminopeptidase were studied 
only in intracellular extracts with a substrate concentration of 2 mM in the 
absence and presence of beta-alanyl-melphalan (0.68 mM). Beta-alanyl- 
melphalan inhibited L-leucine aminopeptidase activity in the intracellular extracts 
of mouse Ehrlich ascites tumor cells. Although this study was not completed, the 
preliminary results indicate that beta-alanyl-melphalan might inhibit L-leucine 
aminopeptidase activity via mechanisms similar to those of melphalan.
VII. In Vitro Toxicity Testing of Melphalan and Beta-alanyl-melphalan:
The objective of the toxicity-testing was to assess the ability of melphalan and 
beta-alanyl-melphalan to decrease the metabolic viability of the mouse Ehrlich 
ascites tumor cells, mouse liver cells, and mouse 3T3 embryonic cells. Mouse 
liver cells and mouse 3T3 embryonic cells were used as control non-neoplastic 
cell lines. An effort was made to test each cell line during the exponential 
growth phase. Exponential growth cultures were exposed, for 24 hours, to the 
test drug at the concentrations indicated (0.001 mM to 0.1 mM). Cell viability 
was subsequently assessed by trypan blue exclusion. Trypan blue is a vital dye 
which can penetrate through the cell membrane of metabolically dead cells giving 
them a blue appearance under light microscopic examination. The living cells are 
able to exclude the dye and maintain a clear appearance. The percentage of 
dead cells is obtained by dividing the number of dead cells (blue cells) by the 
number of total cells (blue cells plus clear cells) and multiplying by 100. This
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value was then converted to log10 value (log10% dead cells).
Toxicity of beta-alanine. 1-aminoethvl phosphonic acid, beta-alanvl-aminoethvl 
phosphonic acid and beta-alanvl-L-alanine against mouse Ehrlich ascites tumor 
cells: Table 8 presents the results describing the effects of beta-alanine, 
1-aminoethyl phosphonic acid (1-AEPA), beta-alanyl-aminoethyl phosphonic acid 
(beta-alanyl-AEPA), beta-alanyl-L-alanine, melphalan and beta-alanyl-melphalan 
treatment (in vitro! on the metabolic cell death of mouse Ehrlich ascites tumor 
cells. Beta-alanine at concentrations of 0.1 mM and 1.0 mM resulted in cell 
death approximating 24.13% and 23.63%, respectively. Neither concentration of 
beta-alanine provides for cell death which was significantly different from control 
nontreated cells (p > 0.05, ANOVA). 1-AEPA also showed no significant 
increase in cell death at concentrations of 0.1 mM and 1.0 mM, i.e. cell death of 
20.48% and 21.51%, respectively (p > 0.05, ANOVA). Beta-alanyl-AEPA, which 
is a dipeptide form of AEPA, in concentrations of 0.1 mM and 0.01 mM resulted 
in cell death of 27.06% and 33.78%, respectively. Cell death due to beta-alanyl- 
AEPA treatments were not significantly different from the control nontreated 
cells (p > 0.05, ANOVA) at both concentrations tested. Beta-alanyl-L-alanine at 
a concentration of 1.0 mM was not significantly toxic when (p > 0.05, ANOVA) 
the percentage of cell death (22.9%) was compared to the control nontreated 
cells (22.78%).
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Table 8. The effects of beta-alanine, 1-aminoethyl phosphonic acid (1- AEPA), 
beta-alanyl-aminoethyl phosphonic acid (beta-alanyl-AEPA), beta-alanyl-alanine, 
melphalan and beta-alanyl-melphalan treatment in vitro on the metabolic cell 
death of mouse Ehrlich ascites tumor cells.
Treatment’ Dosage (mM) % dead cells
control 0 22.78 ± 1.56
beta-alanine 0.1 24.13 ± 0.84'
beta-alanine 1.0 23.63 ± 7.75'
1-AEPA 0.1 20.48 ± 4.83'
1-AEPA 1.0 21.51 ± 0.89'
beta-alanyl-AEPA 0.1 27.06 ± 8.73'
beta-alanyl-AEPA 1.0 33.78 ± 6.13'
beta-alanyl-L-alanine 1.0 22.90 ± 4.18'
melphalan 0.001 33.11 ± 1.36d
melphalan 0.01 54.95 ± 1.98d
melphalan 0.1 89.43 ± 1.57d
beta-alanyl-melphalan 0.001 31.57 ± 1.47d
beta-alanyl-melphalan 0.01 37.94 ± 2.99d
beta-alanyl-melphalan 0.1 81.38 ± 1.27d
a. Treatment as 24 hours incubation starting 48 hours after tumor cell inoculation 
(1 million cells per T-25 flask).
b. Metabolic cell death was assessed by trypan blue exclusion and is expressed as 
percent dead cells.
c. Mean ± SD of 9 flasks from 3 separate experiments.
d. Significantly different from control; p< 0.001 by ANOVA.
e. Not significantly different from control; p>0.05 by ANOVA.
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Toxicity of melphalan and beta-alanvl-melphalan against mouse Ehrlich ascites 
tumor cells: Melphalan at concentrations of 0.001 mM, 0.01 mM, and 0.1 mM 
caused a significant increase in cell death, i.e. 33.11%, 54.95% and 89.43%, 
respectively when compared to the control nontreated cells (p< 0.001 for all 
concentrations, ANOVA). Figure 30 represents a visual presentation of these 
results showing logI0% dead cells versus melphalan concentration. As the 
concentration of melphalan is reduced, the toxicity diminishes in a nonlinear 
manner until at 0.001 mM, cell viability approaches that of nontreated tumor 
cells.
Beta-alanyl-melphalan treatment resulted in cell death values of 31.57%, 
37.94% and 81.38% at concentrations of 0.001 mM, 0.01 mM and 0.1 mM, 
respectively. These values were significantly different from the control nontreated 
cells (p < 0.01 for 0.001 mM and 0.01 mM, p < 0.001 for 0.1 mM, ANOVA). 
Toxicity of beta-alanyl-melphalan to the mouse Ehrlich ascites tumor cells over 
the concentration range of 0.001 mM to 0.1 mM (Figure 31) revealed a positive 
linear correlation of log10% cell death with concentrations of beta-alanyl- 
melphalan. The activity of beta-alanyl-melphalan against mouse Ehrlich ascites 
tumor cells was not significantly different from that of melphalan at a 
concentration of 0.001 mM (p < 0.01, ANOVA). Melphalan was more effective 
than beta-alanyl-melphalan, at 0.01 mM (p < 0.01, ANOVA) and 0.1 mM (p < 
0.01, ANOVA), against mouse Ehrlich ascites tumor cells.
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Figure 30. Toxicity assay in vitro of melphalan toward mouse Ehrlich ascites 
tumor cells. Cells in exponential growth (2 days old) were incubated for 
24 hours with melphalan at the concentrations indicated. Metabolic 
viability was assayed by trypan blue exclusion. The number of cells stained 
blue was divided by the total number of cells counted and multiplied by 
100 to get percent dead cells (%). This value was then converted to logI0 
(log,o%).
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Figure 31. Toxicity assay in vitro of beta-alanyl-melphalan toward mouse Ehrlich 
ascites tumor cells. Cells in exponential growth (2 days old) were 
incubated for 24 hours with beta-alanyl-melphalan at the concentrations 
indicated. Metabolic viability was assayed by trypan blue exclusion. The 
number of cells stained blue was divided by the total number of cells 
counted and multiplied by 100 to get percent dead cells (%). This value 
was then converted to log,0 (log10%).
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Toxicity of melphalan and beta-alanvl-melphalan against mouse liver cells: 
Toxicity studies of melphalan using the mouse liver cells revealed an increase in 
percent of cell death of 14.36%, 14.88% and 34.88% at melphalan concentrations 
of 0.001 mM, 0.01 mM and 0.1 mM, respectively (Table 9). These values are 
significantly different from the percent of cell death value of the control 
nontreated mouse liver cells (p < 0.05 for 0.001 mM and 0.01 mM, p < 0.001 for 
0.1 mM, ANOVA). The data plot of log10% cell death versus melphalan 
concentration revealed a positive linear correlation of toxicity with melphalan 
concentration (Figure 32).
Analysis of toxicity of beta-alanyl-melphalan towards the mouse liver cells 
revealed a slight increase in the percent of cell death, i.e. 7.79%, 7.97% and 
8.76%, at concentrations of 0.001 mM, 0.01 mM and 0.1 mM, respectively (Table 
9). These values are not significantly different from the percent of cell death 
value of the control nontreated liver cells (p > 0.1 for all concentrations, 
ANOVA). A positive linear correlation was observed for log10% cell death versus 
beta-alanyl-melphalan concentrations in treatments of mouse liver cells (Figure 
33). The cytotoxicity of beta-alanyl-melphalan against mouse liver cells was 
significantly less than that of melphalan at all concentrations used (p < 0.05 for 
0.001 mM and 0.01 mM, p < 0.001 for 0.1 mM, ANOVA). It is emphasized that 
none of these values were significantly different from each other or control 
nontreated cells.
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Table 9. The effects of melphalan and beta-alanyl-melphalan treatment (in vitro) 
on the metabolic cell death of mouse liver cells.
Melphalan Beta-alanyl-melphalan
Cone, Logic % % Logio % %
Control 0.77 ± 0.20 6.40 ± 2.73 0.77 ± 0.20 6.40 ± 2.73
0.001 mM 1.15 ± 0.06 14.36 ± 1.93b 0.88 ± 0.09 7.79 ± 1.69c
0.01 mM 1.17 ± 0.06 14.88 ± 2.23b 0.89 ± 0.12 7.97 ± 2.15c
0.1 mM 1.52 ± 0.17 34.88 ± 2.54b 0.94 ± 0.09 8.76 ± 1.85e
Treatments of 24 hours incubation of monolayer cell cultures starting 48 hours 
after mouse liver cell inoculation (1 million cells per T-25 flask). Metabolic cell 
death was assessed by tiypan blue exclusion and is expressed as percent dead 
cells and log10% dead cells.
a. Mean ± SD of 9 flasks from three separate experiments.
b. Significantly different from control; p< 0.001 by ANOVA.
c. Not significantly different from control; p>0.05 by ANOVA.
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Figure 32. Toxicity assay in vitro of melphalan toward mouse liver cells. Cells in 
exponential growth (2 days old) were incubated for 24 hours with 
melphalan at the concentrations indicated. Metabolic viability was assayed 
by trypan blue exclusion. The number of cells stained blue was divided by 
the total number of cells counted and multiplied by 100 to get percent 
dead cells (%). This value was then converted to logl0 (log10%).
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Figure 33. Toxicity assay in vitro of beta-alanyl-melphalan toward mouse liver
cells. Cells in exponential growth (2 days old) were incubated for 24 hours 
with beta-alanyl-melphalan at the concentrations indicated. Metabolic 
viability was assayed by trypan blue exclusion. The number of cells stained 
blue was divided by the total number of cells counted and multiplied by 
100 to get percent dead cells (%). This value was then converted to logi0 
(log10%).
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Toxicity of melphalan and beta-alanyl-melphalan against mouse 3T3 embryonic 
cells: Analysis of toxicity of melphalan towards the 3T3 mouse embryonic cells 
over the same concentration range utilized against the tumor and liver cells 
revealed an increase in the percent of cell death of 19.05%, 20.42% and 47.86% 
at melphalan concentrations of 0.001 mM, 0.01 mM and 0.1 mM, respectively 
(Table 10). The cytotoxicity of melphalan at concentrations of 0.001 mM and 
0.01 mM was not significantly different from the control (p > 0.5 for 0.001 mM 
and p > 0.1 for 0.01 mM, ANOVA), and only the concentration of 0.1 mM was 
significantly different from the control (p < 0.001, ANOVA). Unlike the 
melphalan toxicity study in tumor cells, the data plot of log,„% cell death versus 
melphalan concentration for the 3T3 cells revealed a positive linear correlation of 
cell death with melphalan concentrations between 0.1 and 0.001 mM (Figure 34).
Equivalent testing of beta-alanyl-melphalan for toxicity to mouse 3T3 
embryonic cells (Table 10) revealed that over the concentration range 0.001 mM 
to 0.1 mM, beta-alanyl-melphalan was dramatically more toxic to the mouse 3T3 
embryonic cells than to the tumor cells or liver cells. Beta-alanyl-melphalan 
treatments yielded cell death values of 25.85%, 31.62% and 67.61% at 
concentrations of 0.001 mM, 0.01 mM and 0.1 mM, respectively. These values 
were significantly different from the control nontreated cell values (p < 0.001 for 
all concentrations used, ANOVA). Beta-alanyl-melphalan-treated cells exhibited 
a positive linear correlation of logI0% cell death with increasing concentrations 
(Figure 35).
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Table 10. The effects of melphalan and beta-alanyl-melphalan treatment (in 
vitrol on the metabolic cell death of mouse 3T3 embryonic cells.
Melphalan Beta-alanyl-melphalan
Cone. Logic % % Logic % %
Control 1.26 ± 0.18 18.20 ± 1.53 0.89 ± 0.13 7.76 ± 1.34
0.001 mM 1.28 ± 0.24 19.05 ± 1.75c 1.41 ± 0.19 25.85 ± 1.55b
0.01 mM 1.31 ± 0.23 20.42 ± 1.68c 1.50 ± 0.20 31.62 ± 1.59b
0.1 mM 1.68 ± 0.23 47.86 ± 1.71b 1.83 ± 0.13 67.61 ± 1.36b
Treatments of 24 hours incubation of monolayer cell cultures starting 48 hours 
after mouse 3T3 embryonic cell inoculation (1 million cells per T-25 flask). 
Metabolic cell death was assessed by trypan blue exclusion and is expressed as 
percent dead cells and log10% dead cells.
a. Mean ± SD of 9 flasks from three separate experiments.
b. Significantly different from control; p<  0.001 by ANOVA.
c. Not significantly different from control; p>0.05 by ANOVA.
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Figure 34. Toxicity assay in vitro of melphalan toward mouse 3T3 embryonic
cells. Cells in exponential growth (2 days old) were incubated for 24 hours 
with melphalan at the concentrations indicated. Metabolic viability was 
assayed by trypan blue exclusion. The number of cells stained blue was 
divided by the total number of cells counted and multiplied by 100 to get 
percent dead cells (%). This value was then converted to log10 (log10%).
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Figure 35. Toxicity assay in vitro of beta-alanyl-melphalan toward mouse 3T3 
embryonic cells. Cells in exponential growth (2 days old) were incubated 
for 24 hours with melphalan at the concentrations indicated. Metabolic 
viability was assayed by trypan blue exclusion. The number of cells stained 
blue was divided by the total number of cells counted and multiplied by 
100 to get percent dead cells (%). This value was then converted to log10 
(log,0%).













































The final results of toxicity testing of melphalan revealed that melphalan was 
toxic to mouse liver cells and mouse Ehrlich ascites tumor cells at all 
concentrations tested and is only toxic to mouse 3T3 embryonic cells at a 
concentration of 0.1 mM. Figure 36 illustrates a comparison of the effects of 
melphalan (0.1 mM) and beta-alanyl-melphalan (0.1 mM) on the three different 
cell lines. The results revealed that melphalan is more toxic to the mouse liver 
cells, i.e. increasing the percent of cell death from 7.76% for control liver cells to 
42.29% cell death for melphalan-treated liver cells. Cell death was 7.76% for 
control mouse Ehrlich ascites tumor cells compared to 30.50% cell death for 
melphalan-treated mouse Ehrlich ascites tumor cells. In mouse 3T3 embryonic 
cells, melphalan treatment only increased the percent of cell death from 7.76% 
for the control mouse 3T3 embryonic cells to 20.40% of cell death of melphalan- 
treated mouse 3T3 embryonic cells (Figure 36).
The results further indicated that beta-alanyl-melphalan is toxic to mouse 
Ehrlich ascites tumor cells and mouse 3T3 embryonic cells at all concentrations 
tested and is not toxic to the mouse liver cells at any concentration tested. 
Beta-alanyl-melphalan at a concentration of 0.1 mM caused 27.70% cell death in 
mouse Ehrlich ascites tumor cells. Beta-alanyl-melphalan treatment at a 
concentration of 0.1 mM only increased the percent of cell death from 7.76% for 
the control mouse liver cells to 10.63% for the beta-alanyl-melphalan treated 
mouse liver cells. In mouse 3T3 embryonic cells, beta-alanyl-melphalan treatment
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 36. The effects of 0.1 mM melphalan and 0.1 mM beta-alanyl-melphalan 
in vitro on metabolic viability of mouse Ehrlich ascites tumor cells 
(Ehrlich), mouse liver cells (Liver) and mouse 3T3 embryonic cells (3T3). 
Metabolic viability was assayed by trypan blue exclusion. The percent of 
dead cells represents the number of cells stained blue divided by the total 
number of cells counted and multiplied by 100. In order to compare the 
results, data were normalized by the percent of dead cells in the control 
group (7.76%).
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dramatically increased the percent of cell death from 7.76% for the control 
mouse 3T3 embiyonic cells to a 67.61% cell death for the beta-alanyl-melphalan 
treated mouse 3T3 embryonic cells (Figure 36).
In summary, melphalan at a concentration of 0.1 mM is more toxic to mouse 
liver cells than mouse Ehrlich ascites tumor cells and mouse 3T3 embryonic cells 
while beta-alanyl-melphalan at a concentration of 0.1 mM is more toxic to mouse 
3T3 embryonic cells than mouse Ehrlich ascites tumor cells and is not toxic to 
mouse liver cells.
VIH. In Vitro Cell Survival Testing of Melphalan and Beta-alanyl-melphalan:
The objective of the cell survival study was to assess the ability of melphalan 
and beta-alanyl-melphalan to affect the proliferation activity of the mouse Ehrlich 
ascites tumor cells, mouse liver cells and mouse 3T3 embryonic cells. Sensitivity 
to a 2-hour treatment with melphalan and beta-alanyl-melphalan was compared 
among the three cell lines by assessing in vitro growth after treatment (see 
materials and methods).
Figure 37 illustrates the results of a 2-hour incubation with 0.1 mM 
melphalan and 0.1 mM beta-alanyl-melphalan on the subsequent growth of mouse 
Ehrlich ascites tumor cells. The control group of mouse Ehrlich ascites tumor 
cells exhibited a steady increase in cell number with time with a proliferation rate
108
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Figure 37. The effect of 2 hours exposure to melphalan (0.1 mM) and
beta-alanyl-melphalan (0.1 mM) on the growth of mouse Ehrlich ascites 
tumor cells. Cells in exponential growth were incubated for 2 hours with 
0.1 mM melphalan and 0.1 mM beta-alanyl-melphalan then inoculated to 
new cell culture flasks. Total cell number was counted at timed intervals. 
Data were plotted on semi-log paper.
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of 40,000 cells per hour.
Treatment of mouse Ehrlich ascites tumor cells with 0.1 mM melphalan 
resulted in a nearly linear reduction in cell number with time indicating that a 
2-hour treatment resulted in a time-dependent cell death. Within the first 16 
hours post treatment, the number of mouse Ehrlich ascites tumor cells declined 
by 33.5% and then 65% at 72 hours post treatment for a cell reduction rate of 
20,000 cells per hour.
Treatment of mouse Ehrlich ascites tumor cells with 0.1 mM beta-alanyl- 
melphalan resulted in a dramatic decline in cell numbers to approximately 71% 
of the initial cell number in the first 16 hours. Sixteen hours after treatment, the 
decline in cell number became linear exhibiting a cell reduction rate of 1,550 
cells per hour and reaching a final cell reduction of 79% of the initial number 
after 72 hours.
These results indicate that both agents not only affected cell proliferation, 
restricting the ability of cells to resume replication, but also resulted in cell death 
and lysis. The results also reveal that beta-alanyl-melphalan was significantly 
more effective than melphalan in killing and inhibiting subsequent mouse Ehrlich 
ascites tumor cell proliferation (p < 0.001, ANCOVA).
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Figure 38 presents the results of a 2-hour incubation with 0.1 mM melphalan 
and 0.1 mM beta-alanyl-melphalan on the growth of mouse liver cells. The 
control group of nontreated mouse liver cells showed a slower growth rate 
(60,000 cells per hour) when compared to the control group of mouse Ehrlich 
ascites tumor cells.
Treatment of mouse liver cells with 0.1 mM melphalan resulted in an initial 
slight increase in cell number with time (3,000 cells per hour) for the first 48 
hours post treatment. After 48 hours post treatment, cell numbers increased at a 
faster rate of 20,000 cells per hour. This rate was however only about 33 % of 
the proliferation rate of nontreated mouse liver cells.
Treatment of mouse liver cells for 2 hours with 0.1 mM beta-alanyl- 
melphalan resulted in a growth rate of 50,000 cells per hour. This growth rate 
was about 80% of the growth rate of the control nontreated mouse liver cells 
indicating that mouse liver cells are relatively insensitive to treatment with 
beta-alanyl-melphalan. These results reveal that melphalan dramatically affected 
mouse liver cell proliferation immediately after treatment but that cell replication 
resumed at a less reduced rate approximately 48 hours post-treatment. Beta- 
alanyl-melphalan only slightly restricted the growth rate of mouse liver cells and 
this reduction was not significant. These results also reveal that mouse liver cells 
respond to both agents differently than mouse Ehrlich ascites tumor cells 
indicating that mouse liver cells are insensitive to beta-alanyl-melphalan and were
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Figure 38. The effect of 2 hours exposure to melphalan (0.1 mM) and
beta-alanyl-melphalan (0.1 mM) on the growth of mouse liver cells. Cells 
in exponential growth were incubated for 2 hours with 0.1 mM melphalan 
and 0.1 mM beta-alanyl-melphalan then inoculated to new cell culture 
flasks. Total cell number was counted at timed intervals. Data were 
plotted on semi-log paper.
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only delayed in cellular proliferation by melphalan.
Figure 39 illustrates the results of a 2-hour incubation with 0.1 mM 
melphalan and 0.1 mM beta-alanyl-melphalan on the growth of mouse 3T3 
embryonic cells. The control group of mouse 3T3 embryonic cells exhibited a 
growth rate of 23,000 cells per hour.
Results of these experiments reveal that beta-alanyl-melphalan is more toxic 
than melphalan to mouse 3T3 embryonic cells. Treatment of mouse 3T3 
embryonic cells with 0.1 mM melphalan resulted in a dramatic decline in cell 
number, i.e. approximately 62.3% of the initial cell number within 42 hours after 
treatment for a cell reduction rate of 17,000 cells per hour. Forty-two hours after 
treatment, the cell number began to increase at a rate of 6,000 cells per hour. 
This rate represents a growth potential equivalent to 26% of the control growth 
rate of nontreated mouse 3T3 embryonic cells. Treatment of mouse 3T3 
embryonic cells with 0.1 mM beta-alanyl-melphalan resulted in an equally 
dramatic decline in cell number, i.e. approximately 63.1% of the initial cell 
number within 16 hours after treatment for a cell reduction rate of 40,000 cells 
per hour. Sixteen hours after treatment, cell numbers increased at a rate of 1,750 
cells per hour over 32 hours eventually assuming a rate of 10,000 cells per hour. 
This latter proliferation rate approximated 40% of the cell proliferation rate of 
nontreated mouse 3T3 embryonic cells.
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Figure 39. The effect of 2 hours exposure to melphalan (0.1 mM) and
beta-alanyl-melphalan (0.1 mM) on the growth of mouse 3T3 embryonic 
cells. Cells in exponential growth were incubated for 2 hours with 0.1 mM 
melphalan and 0.1 mM beta-alanyl-melphalan then inoculated to new cell 
culture flasks. Total cell number was counted at timed intervals. Data 
were plotted on semi-log paper.
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IX. Morphological Studies:
Effect of melphalan and beta-alanvl-melphalan on the morphology of mouse 
Ehrlich ascites tumor cells using scanning electron microscopy: The SEM 
micrographs demonstrate the classic characteristics of transformed cells (mouse 
Ehrlich ascites tumor cells) in Figures 40a and 40b. The cell population was 
composed predominantly of spherical cells but bipolar cells were also observed. 
The cell diameter varied from 10 uM to 30 uM and the surfaces of the cells 
contained short microvilli. Filopodia attached the cell to the substrate and small 
ruffles could be seen on the top surface and marginal regions of the cells. Blebs 
could be found on some cell surfaces associated with other cytopodia, (i.e. 
microvilli, filopodia), whereas other cells demonstrated only blebs — giving them a 
"bubbly" appearance.
The SEM micrographs of mouse Ehrlich ascites tumor cells treated with 0.1 
mM melphalan for 24 hours are shown in Figures 41a, 41b and 41c. Cell 
densities were decreased when compared to the mouse Ehrlich ascites tumor cell 
controls (Figure 40a), and a greater variation in cell size and shape of treated 
cells was observed. Damaged cells appeared flattened and had lost significant 
portions of plasma membrane leaving behind a sponge-like mass.
Mouse Ehrlich ascites tumor cells treated with 0.1 mM beta-alanyl-melphalan 
for 24 hours (Figures 42a, 42b and 42c) demonstrated a dramatic reduction of
115
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Figures 40 (a-b). Scanning electron micrograph of monolayer cell culture of 
mouse Ehrlich ascites tumor cells which were treated with Dulbecco’s 
phosphate buffered saline. Cells are covered by microvilli (M), and blebs 
(B). Filopodia (F) are seen attaching to the substrate. Small ruffles (R) 
are seen on the facing surface, (a. 263X, b. 1,774X).
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Figures 41 (a-c). Scanning electron micrograph of a monolayer cell culture of 
mouse Ehrlich ascites tumor cells which were treated with 0.1 mM 
melphalan for 24 hours. Damaged cells (*) are clearly illustrated.
Absence of cell membrane is well demonstrated (Figure 41c). (a. 109X, b. 
938X, c. 1.368X).
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Figures 42 (a-c). Scanning electron micrograph of a monolayer cell culture of
mouse Ehrlich ascites tumor cells which were treated with 0.1 mM
beta-alanyl-melphalan for 24 hours, (a. 148X, b. 1,323X, c. 906X).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
cell density and a reduction or absence of the cytopodia found with nontreated 
cells. Damaged cells were more common. The appearance of these cells was 
exhibiting an appearance similar to that of the melphalan-treated cells.
Effect of melphalan and beta-alanvl-melphalan on morphology of mouse liver 
cells using scanning electron microscopy: The SEM micrographs of control 
mouse liver cells revealed a dense monolayer of well attached cells (Figures 43a 
and 43b). Many round and spindle shaped cells and multiple cell clusters were 
also observed. Surface features included those cytopodia typically found in 
normal liver cells, i.e. microvilli, pseudopodia and filopodia.
Mouse liver cell cultures treated 24 hours with 0.1 mM melphalan (Figures 
44a and 44b) exhibited a marked decrease in cell density. Bipolar and multipolar 
cells demonstrated a flattened appearance and shrinkage at the marginal regions 
where they anchored to the culture dish. Round cells demonstrated an irregular 
shape and cell surfaces that retained the microvilli and filopodia characteristic of 
nontreated cells.
Mouse liver cells treated with 0.1 mM beta-alanyl-melphalan for 24 hours 
(Figures 45a and 45b) demonstrated the typical dense monolayer of well attached 
cells found in the control nontreated mouse liver cells. There was no significant 
reduction in cell density and bipolar, multipolar and round cells maintained their 
shape better than melphalan-treated cells. The typical cell was also less flattened
119
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Figures 43 (a-b). Scanning electron micrograph of a monolayer cell culture of 
mouse liver cells which were treated with Dulbecco’s phosphate buffered 
saline. These control mouse liver cells demonstrate microvilli (M), 
filopodia (F), and pseudopodia (P). (a. 269X, b. 1,843X).
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Figures 44 (a-b). Scanning electron micrograph of a monolayer cell culture of
mouse liver cells which were treated with 0.1 mM melphalan for 24 hours
(a. 280X, b. 1.768X).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figures 45 (a-b). Scanning electron micrograph of a monolayer cell culture of
mouse liver cells which were treated with 0.1 mM beta-alanyl-melphalan
for 24 hours (a. 268X, b. 2,670X) .
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but did exhibit some shrinkage at the marginal attachment areas. Surface 
cytopodia were common.
Effect of melphalan and beta-alanvl-melphalan on morphology of mouse Ehrlich 
ascites tumor cells using light microscopy: A  light microscope photograph of 
mouse Ehrlich ascites tumor cells is presented in Figure 46. Polymorphonucleated 
cells were clearly visible. Cell surfaces were irregular and cytoplasm was filled 
with vacuoles. In some cells, large vacuoles, were observed, which appeared to 
displace the nucleus peripherally.
Mouse Ehrlich ascites tumor cells which were treated with 0.1 mM melphalan 
for 24 hours (Figure 47) exhibited less vacuolated and more dense granular 
inclusions in the cytoplasm than the control nontreated mouse Ehrlich ascites 
tumor cells (Figure 46). Large vacuolated cells demonstrated a collapsed 
morphology and cell debris was observed.
In Figure 48, beta-alanyl-melphalan treated mouse Ehrlich ascites tumor cells 
exhibited a greatly increased amount of cell debris when compared with the 
control nontreated mouse Ehrlich ascites tumor cells. Cells were also less 
vacuolated than control nontreated mouse Ehrlich ascites tumor cells.
Effect of melphalan and beta-alanvl-melphalan on morphology of mouse liver 
cells using light microscopy: The light microscope photograph of mouse liver
123
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Figure 46. Light microscope photograph of mouse Ehrlich ascites tumor cells
which were treated with Dulbecco’s phosphate buffered saline (400X).
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Figure 47. Light microscope photograph of mouse Ehrlich ascites tumor cells
which were treated with 0.1 mM melphalan for 24 hours (400X).
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Figure 48. Light microscope photograph of mouse Ehrlich ascites tumor cells
which were treated with 0.1 mM beta-alanyl-melphalan for 24 hours
(400X).
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cells is shown is Figure 49. Irregular cell surfaces were seen and represented 
typical surface morphology i.e. microvilli. Cells demonstrated highly vacuolated 
cytoplasm and typical nuclei were observed.
Mouse liver cells treated with 0.1 mM melphalan for 24 hours (Figure 50) 
exhibited a gross vacuolation of the cytoplasm. Much cell debris was observed 
which indicating the cells were extensively disrupted by the treatment. Cells 
contained marked numbers of dense granular bodies and smoother surfaces than 
the control nontreated mouse liver cells.
In Figure 51, 0.1 mM beta-alanyl-melphalan-treated mouse liver cells revealed 
an appearance similar to that found in the control nontreated mouse liver cells. 
Cells contained small vacuoles and a single nucleus.
Effect of melphalan and beta-alanyl-melphalan on morphology of mouse Ehrlich 
ascites tumor cells using transmission electron microscopy: Figures 52a, 52b, 52c 
shows the ultrastructure of a representative intact mouse Ehrlich ascites tumor 
cell in which the cytoplasmic organelles appeared typical for a neoplastic cell.
The cell displayed a large nucleus containing a characteristically prominent 
nucleolus with a tightly woven nucleonema (Figure 52a). There was a moderate 
degree of chromatin condensation with clumping of the heterochromatin in the 
vicinity of the nucleolus (Figure 52b). Perichromatin granules were also seen at 
the periphery of the nucleus (Figures 52a, 52b, 52c). A nuclear invagination and
127
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Figure 49. Light microscope photograph of mouse liver cells which were treated
with Dulbecco’s phosphate buffered saline (400X).
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Figure 50. Light microscope photograph of mouse liver cells which were treated
with 0.1 mM melphalan for 24 hours (400X).
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Figure 51. Light microscope photograph of mouse liver cells which were treated
with 0.1 mM beta-alanyl-melphalan for 24 hours (400X).
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Figures 52 (a-c). Transmission electron microscope photograph of mouse Ehrlich 
ascites tumor cells which were treated with Dulbecco’s phosphate buffered 
saline. Mitochondria (m), rough endoplasmic reticulum (RER) and Golgi 
apparatus (G) are shown in these micrographs as well as lipid droplets (L), 
lysosomes (LY), microvilli (M), and blebs (B). A nucleonema (NL), and 
perichromatin (PC) are seen in each nucleus. Note nucleus invagination 
(*) in Figure 52b and multinucleation in Figure 52c. (a. 18,500X, b. 
12.800X, c. 17.500X).
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nuclear inclusions were also observed (figure 52b). A relatively common finding 
in neoplastic cells is the presence of shallow or deep infoldings of the nuclear 
envelope. Cleaved nuclei having one or two deep invaginations are prominent in 
mouse Ehrlich ascites tumor cells. Large nuclear inclusions consisting of 
cytoplasm delineated by the nuclear envelope (Figure 52b) and normal-looking 
mitochondria, i.e. rod-shaped or oval-shaped, with thin cristae, are seen in the 
cytoplasm. Some tubular rough endoplasmic reticulum was observed and 
numerous free ribosomes and cluster ribosomes were abundant in the cytoplasm. 
Lipid droplets and Golgi apparatus were also visible (Figure 52b). Few 
lysosomes were visible in the cytoplasm and the cell surface showed microvilli 
(Figures 52b, 52c) or blebs (Figure 52c) in some cells.
Figures 53a and 53b show typical mouse Ehrlich ascites tumor cells incubated 
with 0.1 mM melphalan for 24 hours. Morphologically damaged and non­
damaged cells were seen. The majority of cells exhibited an irregularity in shape. 
Morphological non-damaged cells showed an appearance similar to the control 
nontreated mouse Ehrlich ascites tumor cells, i.e. cell membrane with microvilli 
or blebs, large nuclei with nucleoli, nuclear invaginations, nuclear inclusions, 
rough endoplasmic reticulum, ribosomes, lipid droplets, Golgi apparatus, and 
lysosomes. Mitochondria appeared swollen and an increased 
heterochromatization was also seen indicating a reduction in active genetic 
information. Damaged cells were severely disrupted. The number of lysosomes 
and large vacuoles was increased. In the cell shown, the cell membrane was
134
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Figures 53 (a-b). Transmission electron microscope photograph of mouse Ehrlich 
ascites tumor cells which were treated with 0.1 mM melphalan for 24 
hours. Large vacuoles (V) and cell debris (CD) are seen in addition to 
the typical characteristics of mouse Ehrlich ascites tumor cells, (a. 4,940X, 
b. 7,457X).
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destroyed and cytoplasm expelled (Figure 53b).
Figures 54a and 54b show the ultrastructure of mouse Ehrlich ascites tumor 
cells treated with 0.1 mM beta-alanyl-melphalan for 24 hours. The majority of 
cells examined showed great amounts of cell debris. Mitochondria appeared 
swollen and an increasing number of lysosomes could be seen. Aggregations of 
heterochromatin appeared to have migrated to the peripheral area of the nucleus.
Effect of melphalan and beta-alanyl-melphalan on morphology of mouse liver 
cells using transmission electron microscopy: As observed with transmission 
electron microscopy, monolayer cultures of mouse liver cells possessed the well- 
defined features characteristic of mouse liver cells. Cytoplasm contained a single 
nucleus, and many mitochondria. A variable number of small electron-lucent 
vesicles were located in the Golgi region. Some lysosomes, a well-developed 
endoplasmic reticulum, and an abundance of Golgi apparatus were seen in the 
cytoplasm (Figures 55a and 55b).
Figures 56a, 56b and 56c show the ultrastructure of mouse liver cells treated 
with 0.1 mM melphalan for 24 hours. Morphologically damaged and non­
damaged cells were seen. Some cells showed extremely decreased cytoplasmic 
volume and the nucleus occupied approximately 90% of visible cytoplasmic space 
and appeared to push organelles to one end (Figure 56a). The perinuclear space 
was dilated (Figures 56a and 56b). Morphologically damaged cells showed
137
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Figures 54 (a-b). Transmission electron microscope photograph of mouse Ehrlich 
ascites tumor cells which were treated with 0.1 mM beta-alanyl-melphalan 
for 24 hours. Mitochondria (m), Lysosomes (LY), Cell debris (CD), 
Nuclear inclusions (NI), Lipid droplets (L). (a. 14,000X, b. 16.278X).
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Figures 55 (a-b). Transmission electron microscope photograph of mouse liver 
cells which were treated with Dulbecco’s phosphate buffered saline. 
Mitochondria (m), Golgi apparatus (G), Endoplasmic reticulum (ER). (a. 
9,92 IX, b. 11,520X).
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Figures 56 (a-c). Transmission electron microscope photograph of mouse liver 
cells which were treated with 0.1 mM melphalan for 24 hours. Nuclear 
inclusions (NI), Dilated nuclear membrane (arrows), Cell debris (CD), 
Osmiophilic lipid droplets (LD). (a. 24,150X, b. 8,400X, c. 20.800X).
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membrane disruption and the cytoplasm being extruded. The number of 
lysosomes was dramatically increased and dark granules were observed (Figure 
56b). Some cells showed severe damage (Figure 56c). Cell membranes, nuclear 
membranes as well as most of the organelles were totally destroyed. Only some 
lysosomes and nuclear material could be recognized (Figure 56c). These results 
indicated that melphalan is extremely toxic to the mouse liver cells.
Figures 57a and 57b show the ultrastructure of mouse liver cells treated with
0.1 mM beta-alanyl-melphalan for 24 hours. Treated cells appeared similar to 
the control nontreated mouse liver cells. Cytoplasm contained numerous 
organelles, i.e. mitochondria, rough endoplasmic reticulum, free ribosomes, Golgi 
apparatus and lipid droplets (Figures 57a and 57b). Nuclear membranes and cell 
membranes appeared intact. Cell surfaces demonstrated microvilli. These results 
indicated that beta-alanyl-melphalan is not toxic to the mouse liver cells.
X. In Vivo Chemotherapy Assays:
Traditional chemotherapy assays were performed in an effort to assess the 
ability of melphalan and beta-alanyl-melphalan to inhibit the growth of tumor 
cells in vivo. Both compounds had been demonstrated to be toxic to the tumor 
cells in the in vitro assays, and since melphalan had already been demonstrated to 
be toxic to the mouse when utilized at concentrations greater than 15 mg/kg (De 
Barieri, 1983), we chose to test melphalan at a maximum concentration of 10
145
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Figures 57 (a-b). Transmission electron microscope photograph of mouse liver 
cells which were treated with 0.1 mM beta-alanyl-melphalan for 24 hours. 
Mitochondria (m), Golgi apparatus (G), rough endoplasmic reticulum 
(RER), Microvilli (M). (a. 13,736X, b. 22,400X).
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mg/kg.
One million tumor cells were injected intraperitoneally (i.p.) and followed 24 
hours later by the drug treatment (also injected i.p.). The body weight, food and 
water consumption were monitored daily in each group as well as the survival 
time for each mouse.
Figure 58 shows the average body weight of mice receiving approximately 1 
million tumor cells at day 0 followed by drug treatment on day 1. The average 
body weight of the control group of mice (i.e. no drug treatment) increased 
significantly 9 days after tumor injection to an average body weight of 50 gms.
For the melphalan treatment group, body weight remained steady over the 30-day 
study period (averaging 32.72 gm). These results indicate that melphalan 
significantly inhibited tumor cell proliferation (ANCOVA, p < 0.001). The 
average body weight of the beta-alanyl-melphalan (40 mg/kg) treatment group 
remained constant for the first 21 to 22 days, significantly increasing over initial 
body weight only in the last 8 days of the experiment. During the 30-day study 
period, beta-alanyl-melphalan treated mice increased their body weights 
approximately 20% over the original body weight. Statistical analysis of these 
data revealed that the increased body weights of beta-alanyl-melphalan treated 
mice were significantly lower than the control nontreated mice (p < 0.001, 
ANCOVA). The results indicated that melphalan and beta-alanyl-melphalan 
significantly decreased tumor cell proliferation and ascites fluid production.
148
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Figure 58. The effects of anticancer drug treatment on the body weight of adult 
CF-1 albino mice with tumor cell injection. The mice (6) in each group 
were injected with approximately 1 million tumor cells in Dulbecco’s 
phosphate buffered saline on day 0 followed by Dulbecco’s phosphate 
buffered saline without (0-0) or with 10 mg/kg melphalan (•-•) , or 40 
mg/kg beta-alanyl-melphalan ( a - a )  on day 1. Body weight was recorded 
daily and average body weight was calculated as Mean ± SD in gm and 
plotted as a function of time. By day 20, all mice in the DPBS treatment 
group had died.
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To examine the effect of both agents on body weight of noncancerous mice, 
CF-1 mice received an injection of Dulbecco’s phosphate buffered saline (DPBS) 
at day 0 followed by DPBS as control, 10 mg/kg melphalan in DPBS, or 40 
mg/kg beta-alanyl-melphalan in DPBS at day 1. Average body weights of 31.59 
gm, 37.59 gm, and 32.79 gm were found for control, melphalan, and beta-alanyl- 
melphalan injected mice over the 30 day study period respectively. Figure 59 
shows that the body weight of animals treated with 10 mg/kg melphalan and 40 
mg/kg of beta-alanyl-melphalan were not significantly different from those of 
control mice. No deaths occurred in mice given 10 mg/kg and 40 mg/kg beta- 
alanyl-melphalan.
To assess the effects of both drugs in daily food and water intake on 
noncancerous mice and tumor-bearing mice, both groups of mice received DPBS, 
melphalan (10 mg/kg) and beta-alanyl-melphalan (40 mg/kg) injection 1 day after 
tumor injection (DPBS injection for noncancerous mice).
The results of the study of daily food and water intake during the 22-day 
study are shown in Figures 60, 61, 62, 63. Figure 60 reveals the average daily 
water consumption of CF-1 mice receiving tumor cells on day 0 and DPBS, 10 
mg/kg melphalan or 40 mg/kg beta-alanyl-melphalan on day 1. The DPBS 
injected group, i.e. no drug treatment, demonstrated a reduction of daily water 
consumption, ie. 8.2 ml to 2.4 ml over the 22 days. Melphalan treated mice
150
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Figure 59. The effects of anticancer drug treatment on the body weight of adult 
CF-1 albino mice with no tumor injection. The mice (6) of each group 
were injected with Dulbecco’s phosphate buffered saline on day 0 followed 
by Dulbecco’s phosphate buffered saline without (O-O), or with 10 mg/kg 
melphalan (•-•), or 40 mg/kg beta-alanyl-melphalan ( a-a) on day 1. Body 
weight was recorded daily and average body weight was calculated as 
Mean ± SD in gm and plotted as a function of time.
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Figure 60. The effects of anticancer drugs on water consumption of
tumor-bearing mice. Daily ad libatum water consumption during a 22-day 
study for tumor-bearing mice which received a 1 million tumor cell 
injection on day 0 and followed by dulbecco’s phosphate buffered saline 
(O-O), 10 mg/kg melphalan (•-•) , 40 mg/kg beta-alanyl-melphalan (*-*) 
injection on day 1. Water consumption was recorded daily and average 
water consumption was calculated as Mean ± SD in ml and plotted as a 
function of time.
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exhibited a steady water intake with an average of 5.65 ml/day. Beta-alanyl- 
melphalan treated mice exhibited fluctuations in water consumption, increasing 
over the first 6 days followed by a plateau for the next 6 days then declining over 
the next 10 days to a value similar to that of the melphalan treated group (2.4 
ml).
Figure 61 reveals that CF-1 mice were injected with Dulbecco’s phosphate 
buffered saline (DPBS) and received DPBS, 10 mg/kg melphalan, and 40 mg/kg 
beta-alanyl-melphalan. Averaged water intake of 5.46 ± 0.81, 5.59 ± 1.27, 7.27 
± 1.24 ml over the 22 days of study were observed. Only the beta-alanyl- 
melphalan group demonstrated a trend of increase in average daily water 
consumption when compared to the control group (p > 0.01, ANCOVA).
Measurements of average daily food consumption in the cancerous groups, i.e. 
injected with 1 million ascites tumor cells on day 0, receiving DPBS therapy on 
day 1, revealed a dramatic decline after 5 days (Figure 62). The melphalan 
treated group of tumor-bearing mice showed a slight increase in food 
consumption but this increase was not significant with increasing time providing 
an average value of 4.51 ± 1.31 gm/day/mouse (Figure 62). The beta-alanyl- 
melphalan treated group of tumor-bearing mice demonstrated a steady food 
consumption with an average of 3.38 ± 0.66 gm/day/mouse (Figure 62). The 
average daily food consumption by the DPBS treated group of tumor-bearing 
mice was significantly different (reduced) from the other treatment groups after
153
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Figure 61. The effects of anticancer drugs on water consumption in noncancerous 
mice. Daily ad libatum water intake during a 22-day study of Dulbecco’s 
phosphate buffered saline injected CF-1 mice (noncancerous mice) which 
received Dulbecco’s phosphate buffered saline on day 0 and followed by 
Dulbecco’s phosphate buffered saline (O-O), 10 mg/kg melphalan (•-•), or 
40 mg/kg beta-alanyl-melphalan ( a - a )  24 hours later. W ater consumption 
was recorded daily and average water consumption (in ml) was calculated 
as Mean ± SD and plotted as a function of time.
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Figure 62. The effects of anticancer drugs on food consumption in tumor-bearing 
mice. Daily ad libatum food consumption during a 22-day study for 
tumor-bearing mice which received 1 million tumor cells on day 0 and 
followed by Dulbecco’s phosphate buffered saline (O-O), 10 mg/kg 
melphalan (• - • ) , or 40 mg/kg beta-alanyl-melphalan (*-*) on day 1. Food 
consumption was recorded daily and average food consumption (in grams) 
was calculated as Mean ± SD and plotted as a function of time.
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day 9 (p < 0.001, ANOVA).
Measurements of average daily food consumption in the noncancerous groups,
i.e. injected with DPBS on day 0 followed by drug treatment on day 1 (Figure 
63), revealed no significant differences between the DPBS treatment (3.60 ± 0.54 
gm/day/mouse), melphalan treatment (4.63 ± 1.13 gm/day/mouse) and beta- 
alanyl-melphalan treatment (4.21 ± 1.15 gm/day/mouse) (p > 0.1, ANOVA).
The average survival times of the mice were recorded in all treatment groups 
and the average T /C  ratio were calculated for each treatment group. The results 
presented in Table 11 represent 2 separate chemotherapeutic assays performed 
over 2 consecutive months with each test group containing five or more animals.
An average survival time of 13.4, 14.5, 18.0 days and an average T /C  ratio of
103.6, 99.4, 108.1% were found for mice treated with concentrations of beta- 
alanine of 10, 20 and 50 mg/kg body weight, respectively. As expected, this 
amino acid did not significantly extend the survival time of cancerous mice 
(ANOVA, p > 0.1).
Treatments of 10 mg/kg, 25 mg/kg, and 50 mg/kg 1-aminoethyl phosphonic 
acid (1-AEPA) in tumor bearing mice resulted in mean survival times of 14.0,
12.8, 18.2 days, respectively and the corresponding percentage of T /C  ratio was
106.6, 84.5 and 110.9% (Table 11). No dose-dependency was found and 1-AEPA
156
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Figure 63. The effects of anticancer drugs on food consumption in noncancerous 
mice. Daily ad libatum food consumption during a 22-day study for 
dulbecco’s phosphate buffered saline injected mice which received 
Dulbecco’s phosphate buffered saline on day 0 and followed by Dulbecco’s 
phosphate buffered saline (O-O), 10 mg/kg melphalan (•-•) , or 40 mg/kg 
beta-alanyl-melphalan (*-*) injection on day 1. Food consumption was 
recorded daily and average food consumption (in grams) was calculated as 
Mean ± SD and plotted as a function of time.
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Table 11. Calculated T/C  ratio from chemotherapy assays.
Treatment Dosage Survival T /C  ratio
(mg/kg) Time (day)
control 0 14.5 ± 3.1 100.0
beta-alanine 10 13.4 ± 0.9 103.6 ± 2.8
beta-alanine 25 14.5 ± 3.7 99.4 ± 16.8
beta-alanine 50 18.0 ± 1.6 108.1 ± 8.9
1-AEPA 10 14.0 ± 1.6 106.6 ± 13.0
1-AEPA 25 12.8 ± 3.5 84.5 ± 7.6
1-AEPA 50 18.2 ± 1.7 110.9 ± 8.3
beta-alanyl-AEPA 10 15.0 + 2.3 114.8 ± 19.2
beta-alanyl-AEPA 25 13.9 ± 1.2 94.6 ± 9.9
beta-alanyl-AEPA 50 15.3 ± 2.9 86.9 ± 9.2
beta-alanyl-L-alanine 25 14.2 ± 3.2 89.8 ± 6.1
melphalan 5* 26.7 ± 4.4 179.9 ± 6.2b
melphalan 10* 28.5 + 2.6 193.9 ± 8.0b
beta-alanyl-melphalan 5 18.0 Hh 2.0 125.8 ± 6.8b
beta-alanyl-melphalan 10 17.5 ± 1.6 125.5 ± 8.6b
beta-alanyl-melphalan 20* 21.6 ± 5.3 144.0 ± 21.0b
beta-alanyl-melphalan 30* 23.3 4.8 139.6 ± 12. lb
beta-alanyl-melphalan 40* 22.5 + 5.7 152.2 ± 16.2b
Mice were injected i.p. with one million cells and after 24 hours, injected i.p. with 
the drug indicated. Controls received equal volumes of buffer (Dulbecco’s 
phosphate buffered saline). The time the mouse died was recorded as survival 
day. The survival day of the treatment group divided by the survival day of the 
control group times 100 gave the T /C  ratio. A T /C  ratio larger than 120 can be 
considered to indicate a potent anticancer drug.
AEPA: aminoethyl phosphonic acid.
* Some mice were still alive after 30 days and were declared "dead" for purposes 
of calculation of the T /C  ratio.
a. Each treatment contained at least 5 mice per assay and each treatment was 
repeated 2-5 times and is expressed as Mean ± SD.
b. Significantly different from control; p< 0.001 by ANOVA.
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did not demonstrate activity against tumors.
Beta-alanyl-AEPA treatments (5 mg/kg, 25 mg/kg, and 50 mg/kg) resulted in 
mean survival times of 15.0, 13.9, 15.3 days and T /C  ratios of 114.8, 94.6 and 
86.9%, respectively. This dipeptide form of aminoethyl phosphonic acid 
demonstrated a  negative correlation of concentration and survival time, i.e. the 
higher the concentration of beta-alanyl-AEPA, the lower T /C  ratio was observed. 
The dipeptide beta-alanyl-alanine also did not significantly extend the survival 
time of cancerous mice (ANOVA, p > 0.1).
Equivalent treatment of cancerous mice with melphalan at 5 mg/kg (the 
lowest concentration tested) yielded an average survival time of 26.7 days and an 
average T /C  ratio of 179.9% ± 6.2. Treatment with 10 mg melphalan/kg gave 
an average survival time of 28.5 days and an average T /C  ratio of 193.9% ± 8.0. 
Values for T /C  ratio larger than 120% indicate considerable anticancer activity. 
The survival time of the cancerous mice was significantly prolonged. As indicated 
in Table 11, the T /C  ratios for melphalan treated mice were arbitrarily low, since 
cancerous mice treated with melphalan routinely survived beyond the 30-day 
"cut-off' time for termination of the assay. Mice surviving beyond 30 days were 
arbitrarily declared "dead" at day 30 in order that a T /C  ratio could be 
calculated. Treatment of cancerous mice with beta-alanyl-melphalan 
concentrations of 5 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, and 40 mg/kg gave 
average survival times of 18.0, 17.5, 21.6, 23.3, and 22.5 days and average T /C
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ratios of 125.8% ± 6.8, 125.5% ± 8.6, 144.0% ± 21.0, 139.6% ± 12.1, and 
152.2% ± 16.2, respectively. Although both the survival time and the T /C  ratios 
appear to exhibit a general upward trend, only those values for the 5 mg/kg and 
40 mg/kg concentrations of dipeptide are significantly different (ANOVA, p <
0.001). It is of interest that the three highest concentrations of dipeptide utilized 
were greater than the concentration of melphalan shown to be toxic to the 
mouse. No toxic reactions to the dipeptide were observed at any concentration 
tested by tumor-bearing mice or by mice having received a sham injection 
(Dulbecco’s phosphate buffered saline followed by drug treatment).
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DISCUSSION
The research described here came about as a result of research on the ability 
of the eukaryotic fungus Neurospora crassa to transport and utilize small peptides 
as sources of nitrogen. The presence of a transport mechanism in this 
microorganism for small tri- to pentapeptides had been suggested (Wolfinbarger 
and Marzluf, 1974), and it was demonstrated that Neurospora crassa was capable 
of growing on peptides as a sole source of leucine only so long as they were small 
enough to be transported by this peptide transport mechanism. In a later study 
(Wolfinbarger and Costellano, 1983), it was demonstrated that Neurospora crassa 
could grow on all sizes of peptideS provided it was forced to utilize the peptides 
as a sole source of nitrogen and leucine. Analysis of the culture media for 
peptidohydrolytic enzymes revealed the interesting observation that growth on the 
larger (nontransportable) peptides resulted from the production and secretion of 
extracellular peptidohydrolytic enzymes, and so long as these peptides were too 
large to be transported by the peptide transport system, the peptides served to 
"induce" the hydrolytic enzymes. Growth on a transportable peptide precluded 
induction and secretion of hydrolytic enzymes. In short, the ability of a peptide 
to act extracellularly in the induction of a physiological response by the
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microorganism, i.e., hydrolytic enzyme production, depended on the ability/ 
inability of the cell to transport it.
As a logical extension to neoplastic cells, it had been reported that Ehrlich 
ascites tumor cells were capable of transporting small peptides (Christensen and 
Rafn, 1952). Indeed, only two additional types of cells, those lining the small 
intestine and the kidney proximal tubules (both noncancerous), have been 
reported as being capable of small peptide transport (Addison et al., 1973; 
Ganapathy and Leibach, 1983). Demonstration of a peptide transport mechanism 
in one type of mammalian cell is indicative of the genetic potential for peptide 
transport in all cells of that mammal and if it is not expressed it must be 
repressed by some undefined regulatory mechanism. Derepression of repressed 
genetic functions in cancer cells is not uncommon, and the assumption that 
noncancerous cells might routinely be incapable of small peptide transport, 
whereas transformation to the cancerous state might result in the derepression of 
this genetic capability, led to this study. Since small peptide hormones are 
accepted as normal regulators of cell function, and cancerous cells appear to be 
altered in their responses to peptide hormones, we reasoned that the ability of 
cancer cells to transport small peptides might preclude the ability of these 
peptides, present in the extracellular environment, to induce a physiological 
response -  a response similar to that observed for Neurospora crassa.
162
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
If this hypothesis is correct, it would mean that some neoplastic cells might be 
capable of small peptide transport, and thus small peptides would be an efficient 
means of targeting toxic amino acid analogues to these cells. It has been 
demonstrated that Ehrlich ascites tumor cells transport small peptides 
(Christensen and Rafn, 1952), and indicated that the incorporation of toxic amino 
acid analogues into small peptides might represent a unique approach in the 
design of a new group of anticancer drugs (Tsay and Wolfinbarger, 1987). The 
potential of small peptide mimetics as useful drug molecules lies largely in their 
ability to act in one of three ways, i.e. as a "carrier" with "targeting" functions, as 
a peptidase inhibitor, or as an antagonist/agonist of a natural peptide hormone or 
transmitter. The possibility of using peptides as carriers of cytotoxic agents has 
been extensively researched as a means of synthesizing more selective antitumor 
agents. Targeting a drug to specific cell types is possible with certain carrier 
functions, many of which are peptides (Firestone et al., 1982). These carrier 
molecules rely largely on their ability to release the active drug moiety at or 
inside the target cells due to the action of selective peptidases. Tumor cells 
produce many hydrolytic enzymes, some of which are in part selective for certain 
tumors, i.e. gamma-glutamyltransferase, plasminogen activator, cathepsin B 
(Weber et al., 1982; Honn et al., 1982) and thus should clearly be capable of 
releasing active drug moieties. Peptide derivatization of cytotoxic agents usually 
renders the drug molecule inactive, until it is in the vicinity of the tumor or inside 
the tumor cells. The carrier is then cleaved away to reveal the toxic compound.
In certain cases peptide derivatization would also appear to enhance selective
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active drug uptake and accumulation by the tumor cells (Firestone et al., 1982).
As mentioned earlier, neoplastic cells characteristically secrete large amounts 
of protein into their environment. Among these proteins, peptidohydrolytic 
enzymes constitute a potential for metastasis and destruction of noncancerous 
tissue. Komatsu et al. (1987) analyzed HeLa, KB, and K-44 carcinoma cell lines 
and observed that the dipeptidyl peptidase II activity was 6- to 24-fold higher in 
carcinoma cell lines than in human fibroblasts. Tsavaris et al. (1988) examined 
the enzyme activity of cancerous tissue and the adjacent normal epithelium of 40 
patients with breast cancer. It was found that the absence of alkaline 
phosphatase and cytochrome oxidase and the presence of leucine aminopeptidase, 
beta-glucuronidase and dehydrogenase in the cancerous tissues was related to 
poor response to chemotherapy and therefore to poor patient survival. On the 
contrary, the presence of cytochrome oxidase and alkaline phosphatase and the 
absence of leucine aminopeptidase, beta-glucuronidase and dehydrogenase in 
cancerous tissues was related to good response of chemotherapy. Kojima et al. 
(1987) studied the changes of glycylproline dipeptidyl aminopeptidase and 
gamma-glutamyl transpeptidase activities, and their subcellular distributions, in 
human hepatic cancer. The activities of glycylproline dipeptidyl aminopeptidase 
in cancer tissues were significantly higher than these found in healthy livers. The 
activity of gamma-glutamyl transpeptidase activity was significantly increased not 
only in cancer tissues but also in liver tissues adjacent to the tumor.
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The finding of cellular peptidase activity in these earlier studies, seems to 
strongly support the results obtained in this study of the peptidohydrolytic 
enzymes associated with mouse Ehrlich ascites tumor cells. The results presented 
in this present study of peptidohydrolytic enzymes confirmed the production and 
secretion of large numbers of peptidohydrolytic enzymes by mouse Ehrlich ascites 
tumor cells. A high level of peptidase activity was observed both in extracellular 
and intracellular extracts. Analysis of intracellular peptidohydrolytic enzyme 
activity demonstrated six major peptidases possessing different R m values on gel 
electrophoresis. Of the 37 peptides tested, 18 were dipeptides and 19 were larger 
than a dipeptide i.e. tripeptides, tetrapeptides, etc. Of the 18 dipeptides, only 4 
were resistant to hydrolysis by intracellular peptidohydrolytic enzymes. Peptides 
containing a beta-alanine at the amino terminal end of the peptide (such as 
beta-alanyl-glycine, beta-alanyl-alanine) were resistant to the hydrolysis and thus 
should make good substrates for study of peptide transport and cancer 
chemotherapy. Of all tripeptides tested only glycyl-L-leucyl-L-tyrosine was 
hydrolyzed by intracellular peptidohydrolytic enzymes. The remaining 
oligopeptides were shown to be resistant to hydrolysis.
Analysis of extracellular peptidohydrolytic enzyme activity in mouse Ehrlich 
ascites tumor cells revealed three major peptidase activities. A total of 29 
peptides were tested against these peptidases. Eleven were dipeptides, 12 were 
tripeptides and 6 were larger than a tripeptide. Among the 11 dipeptides, only 
beta-alanyl-L-alanine and beta-alanyl-glycine were resistant to hydrolysis by the
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extracellular peptidohydrolytic enzymes. These results confirmed that peptides 
containing beta-alanine at the amino terminal end of a peptide were resistant to 
hydrolysis, and suggested a design for anticancer drugs.
Results from the study of peptidohydrolytic enzymes associated with mouse 
Ehrlich ascites tumor cells were different from those of Payne (1973) who studied 
peptide utilization in Escherichia coli - with a specific focus on peptides containing 
beta-alanyl residues. Studies of the growth of Escherichia coli strain M-123 in 
differently supplemented media, revealed that beta-alanyl-glycyl-glycine was 
devoid of nutritional value for M-123. It was suggested that the peptide did not 
enter the organism or that it was resistant to hydrolysis. Electrophoresis of the 
products of peptidase action on tripeptides containing beta-alanine showed that 
beta-alanyl-glycyl-glycine was about 50 % hydrolyzed, and glycine, beta-alanine 
and uncleaved beta-alanyl-glycyl-glycine were detected. Peptidase-treated glycyl- 
glycyl-beta-alanine yielded glycine, glycyl-beta-alanine and uncleaved glycyl-glycyl- 
beta-alanine. No free beta-alanine was detected, indicating that Escherichia coli is 
unable to liberate C-terminal beta-alanyl residues, and that the enzymes may 
have requirements for a C-terminal alpha-carboxyl group. Demonstration of the 
release of free glycine from both glycyl-glycyl-beta-alanine, and beta-alanyl-glycyl- 
glycine makes it unlikely that the nutritional failure of beta-alanyl-glycyl-glycine is 
attributable to lack of peptidase action, and it appears more likely that the 
peptide was inadequately accumulated by Escherichia coli.
166
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Studies in mammalian systems have revealed that peptides containing beta- 
alanine are not well hydrolyzed by mammalian proteolytic enzymes (Hansson and 
Smith, 1948). These researchers found that a carboxypeptidase from frozen beef 
pancreas hydrolyzed carbobenzoxyglycyl-L-phenylalanine about 800 times faster 
than carbobenzoxy-beta-alanyl-DL-phenylalanine. A partially purified preparation 
of prolidase from hog intestinal mucosa hydrolyzed glycyl-L-proline about 30 
times more rapidly than beta-alanyl-L-proline and enzymes from human uterus 
hydrolyzed glycyl-L-leucine about 250 times more rapidly than beta-alanyl-L- 
leucine. Enzyme extracts from human uterus and rat muscle did not hydrolyze 
beta-alanyl-glycine or beta-alanyl-beta-alanine, and slowly hydrolyzed glycyl-beta- 
alanine. A  fresh extract of rat muscle hydrolyzed triglycine very rapidly and 
glycyl-beta-alanyl-glycine and diglycyl-beta-alanine, but the hydrolysis of beta- 
alanyl-glycyl-glycine was slow. This research, in various mammalian systems, is 
consistent with the results obtained in this study of peptidohyrolytic enzyme 
activity from mouse Ehrlich ascites tumor cells. Both extracellular and 
intracellular extracts demonstrated high levels of peptidase activities. Although 5 
peptidases were found in intracellular extracts and only 3 peptidases were found 
in extracellular extracts, none of the enzymes hydrolyzed beta-alanyl-L-alanine or 
beta-alanyl-glycine.
Information obtained from the peptidohydrolytic enzyme activity study lead to 
the decision to synthesize dipeptides containing beta-alanine at the amino 
terminal end and toxic amino acid analogues at the carboxy-terminal end.
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Although most of the tripeptides or peptides larger than a tripeptide tested were 
resistant to hydrolysis, synthesis of dipeptides was chosen, primarily because 
dipeptides are easier to synthesize. The rational for synthesizing beta-alanyl- 
melphalan, as a model drug, was that of creating a substance which was 
simultaneously endowed with cytotoxic activity due to the alkylating group, 
resistant to hydrolysis, and which might be selectively accumulated by neoplastic 
cells. It has been suggested that the introduction of melphalan on a molecular 
carrier, i.e. a dipeptide, in addition to an alkylating effect, would give the drug 
antimetabolic properties (De Barbieri, 1972 and 1983; Yagi, 1984a and 1984b).
Melphalan has been an important alkylating agent for the treatment of 
various cancers including multiple myeloma and ovarian and breast carcinoma, 
since it was first synthesized (Bergel and Stock, 1954). Little information was 
available for approximately twenty years concerning its pharmacokinetic 
properties in human or animals, primarily because of its’ rapid hydrolytic 
degradation, a reaction common to alkylating agents (Chirigos, 1964). In the last 
decade, accurate methods were developed for determining concentrations of 
melphalan (Sweeney, 1985) and these methods have been used in 
pharmacokinetic and drug stability studies (Bosanquet, 1985 and 1988).
Melphalan has been found to be labile in solution, degrading via a cyclic aziridiny 
intermediate to monohydroxymelphalan and then to dihydroxymelphalan (Chang, 
1978). Melphalan does not undergo active in vivo metabolism (Evans, 1982).
The research described here was designed, therefore, to investigate the stability of
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solutions of melphalan and beta-alanyl-melphalan under conditions that pertain to 
the in vitro toxicity assays and in vivo chemotherapy assays. It was anticipated 
that synthesis of the dipeptide containing a nitrogen mustard (melphalan) might 
result in a melphalan containing compound with greater specificity to cancer cells 
and improved stability. The solvent system utilized in this study did not resolve 
monohydroxy melphalan from dihydroxy melphalan, but this did not affect 
separation of breakdown products from the parent drug.
Results presented in this study revealed that melphalan , incubated in 
distilled water at 37° C, had a half-life of 105 minutes, a value which compared 
favorably with the half-life of melphalan determined by Bosanquet (1985). He 
reported that melphalan had a half-life of 2.70 hours at 37° C in normal saline. 
The results of the present study for the stability of melphalan at 0° C further 
supported the observation of Bosanquet (1985). He reported melphalan had a 
half-life of 271 hours at 5° C in normal saline and thus that low temperatures 
increased the stability of melphalan. Both of these studies are at variance with 
the results of Yang and Drewinko (1983) who found that 50% of drug activity 
was lost after storing melphalan at 4° C, -20° C, or -70° C for more than 2 weeks.
Results presented in the present study revealed that decomposition 
(breakdown) of melphalan must be considered as important in in vivo and in 
vitro assays of drug activity. The decreases in melphalan concentrations due to 
chemical decomposition were approximately 39%, 29%, and 34% in 10% bovine
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serum albumin, 30% bovine serum albumin, and NCTC-135 medium with 10% 
fetal bovine serum after 2 hours incubation at 37° C. The corresponding 
hydrolysis rate constants were 0.31 umole/minute, 0.23 umole/minute, and 0.26 
umole/minute. This rate of composition would suggest that during long-term 
incubation, i.e. 24 hours drug treatment studies, the majority of cell damage must 
occur early in the treatment period. It is interesting to note however that the 
absence of protein allows hydrolysis to take place more rapidly than in its’ 
presence. The basis of this difference in decomposition has not been elucidated.
Our findings are consistent with the in vitro studies of Chang et al. (1978a; 
1978b) who also demonstrated that bovine serum albumin or human plasma 
proteins retarded the hydrolysis rate of melphalan in vitro. No change in the 
plasma melphalan concentration was seen when melphalan was stored at -20° C 
for 3 weeks. However, when the same sample was removed from - 20° C and 
placed at 4° C for additional weeks, there was a 35% decrease in the plasma 
melphalan concentration (Chang et al., 1978a). The hydrolysis rate constants of 
melphalan in bovine serum albumin solutions were 0.46 umole/hour (8% bovine 
serum albumin), 0.36 umole/hour (13% bovine serum albumin) and 0.24 
umole/hour (25% bovine serum albumin) (Chang et al., 1978b). It is suggested 
therefore, that melphalan is relatively temperature-sensitive in distilled water, 
losing 54% of its activity in 2 hours at 37° C and is very stable at 0° C. It is more 
stable in bovine serum albumin solutions and shows slightly increased stability at 
higher bovine serum albumin concentrations.
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Incorporation of melphalan into a peptide could lengthen the half-life of the 
alkylating component by reducing intramolecular cyclization and subsequent 
carbonium ion formation of the 2-chloroethyl side chains involved in alkylation.
In addition to a change in the stability of melphalan when incorporated into 
beta-alanyl-melphalan, the linkage of beta-alanine and melphalan could also alter 
the cellular uptake compared with melphalan. It has been reported that 
melphalan enters tumor cells via two leucine-preferring carrier transport systems 
(Goldenberg, et al., 1979), and exogenous amino acids in the transport medium 
effectively inhibit this carrier-dependent uptake, particularly in L1210 leukemia 
cells. Covalent attachment of beta-alanine to melphalan, to yield the dipeptide, 
alters the transport systems used for uptake.
Bifunctional alkylating agents, the first types of drugs to be used in 
chemotherapy of malignant disease, are still an important group of drugs in 
clinical cancer chemotherapy (Colvin,1982). Despite extensive clinical experience 
with these drugs, their mechanisms of action remain inadequately characterized. 
The cytotoxic effects of these drugs are generally considered to involve reactions 
with DNA resulting in various types of DNA damage. Besides monofunctional 
binding of the drug to a single site in the DNA molecule, drug-induced cross- 
linking between bases in the same DNA strand (DNA intrastrand cross-links), 
between complementary strands of the DNA molecule (DNA interstrand cross­
links), and between DNA and protein (DNA-protein cross-links) occur (Colvin,
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1980; Kohn,1979; Hemminki, 1984). Formation of DNA cross-links induced by 
melphalan have been described in several studies involving human tumor cells 
(Hansson, et al., 1987; Lewensohn, et al, 1987). A strong correlation has been 
obtained between the cytotoxicity of melphalan and the DNA interstrand cross 
links, indicating that the initial induction of DNA interstrand cross-links are 
important for the cytotoxic effects of bifunctional alkylating agents (i.e. 
melphalan) (Hansson, 1987). Although the reported mechanism for melphalan 
toxicity towards cells involves its reactivity towards guanine residues in DNA 
(Hansson, et al., 1987), the bifunctional alkylating group at the para-position on 
the aromatic side group of phenylalanine could be reactive towards proteins, i.e. 
through primary amine reactivity. The ability of melphalan to inhibit 
peptidohydrolytic enzymes confirmed that DNA cross linkage is not the only 
mechanism for melphalan toxicity and/or chemotherapeutic activity and future 
studies will be needed to asses the impact of this drug on tumor nutrition and 
metastasis.
The synthetic dipeptide beta-alanyl-melphalan is a new bifunctional alkylating 
agent of the nitrogen mustard group consisting of beta-alanine in the amino- 
terminal end with a bis-(2-chloroethyl) amino group in the para position of the 
benzene ring of the phenylalanine residue. Our in vitro toxicity studies 
demonstrated marked cytotoxic activity of this synthetic dipeptide against mouse 
Ehrlich ascites tumor cells, whereas no cytotoxic activity of beta-alanyl-melphalan 
was found towards mouse liver cells. Degrees of cytotoxicity induced by exposure
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to beta-alanyl-melphalan varied with concentrations. Among the cell lines 
studied, mouse 3T3 embryonic cells were the most sensitive to beta-alanyl- 
melphalan. The cells least sensitive to beta-alanyl-melphalan were mouse liver 
cells. Mouse liver cells were the most sensitive to melphalan whereas the least 
sensitive to melphalan were mouse 3T3 embryonic cells. Therefore, we suggest 
that the mouse 3T3 embryonic cell line may not represent an appropriate control 
cell line for this kind of study. We suspect that the mouse 3T3 embryonic cells 
may be capable of small peptide transport, since they represent a 
"nondifferentiated" cell line (somewhat analogous to neoplastic cells).
Comparisons of mouse Ehrlich ascites tumor cell survival demonstrated that 
prolongation of melphalan treatment from 2 hours to 24 hours did significantly 
increase cellular cytolysis (33.50% versus 89.43%), in contrast, prolongation of 
beta-alanyl-melphalan treatment from 2 hours to 24 hours did not significantly 
increase cellular cytolysis (70.50% versus 81.38%). This observation suggested 
that tumor cells must be exposed to a minimum concentration of melphalan for a 
longer time in order to be irreversibly damaged. In contrast, tumor cells exposed 
to a minimum concentration of beta-alanyl-melphalan for only a short period time 
can be irreversibly damaged.
Comparisons of the cytotoxic effects of beta-alanyl-melphalan in mouse 
Ehrlich ascites tumor cells with those of the parental molecules, i.e. beta-alanine, 
and melphalan or other dipeptides beta-alanyl-L-alanine, beta-alanyl-AEPA
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(which is a dipeptide with an antibacterial toxin aminoethyl phosphonic acid) 
revealed that only melphalan and beta-alanyl-melphalan behaved similarly and 
that the melphalan and beta-alanyl-melphalan both were significantly more 
cancerocidal than beta-alanine, 1-AEPA, beta-alanyl-AEPA, or beta-alanyl-L- 
alanine. The cytotoxic activity of beta-alanyl-melphalan was 3- to 3.5-fold greater 
than the cytotoxicities of equivalent concentrations of beta-alanine, 1-AEPA, beta- 
alanyl-AEPA and beta-alanyl-L-alanine. This increased cytotoxicity could be 
accounted for by a variety of mechanisms. It is possible that beta-alanyl- 
melphalan could exert antimetabolic activity and inhibit protein synthesis as was 
observed following treatment with the multipeptide complex, peptichemio (De 
Barieri, 1972).
The 2-hour beta-alanyl-melphalan treatment survival assay demonstrated that 
tumor cell viability declined significantly with time. This irreversible cytotoxicity 
of the dipeptide was probably attributable to the bis-(2-chloroethyl) amino 
component of the molecule which is involved in strongly electrophilic reactions. 
Alkylation of guanine residues is a primary reaction, and this results in DNA 
miscoding, excision of altered residues, and possible cross-linking of two nucleic 
acid chains or nucleic acids to proteins. As a consequence, toxicity is usually 
expressed at S and G2 phases of the tumor cell cycle (Fumer and Brown, 1980).
It appeared that these cytotoxic effects of beta-alanyl-melphalan were not readily 
repaired by cellular mechanisms, since the viabilities of mouse Ehrlich ascites 
tumor cells continued to decrease throughout the observation period.
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Comparisons of the cytotoxic effects of melphalan and beta-alanyl-melphalan 
in mouse Ehrlich ascites tumor cells revealed that the cytotoxic activity of 
melphalan was either similar to or greater than that of beta-alanyl-melphalan at 
all concentrations used against mouse Ehrlich ascites tumor cells in vitro. These 
results indicated that at equivalent doses in vivo, melphalan and beta-alanyl- 
melphalan should have similar antitumor activities. These results also indicated 
that beta-alanyl-melphalan was not readily hydrolyzed by available extracellular 
peptidohydrolases followed by transport of free melphalan into cells via amino 
acid transport systems. If mouse Ehrlich ascites tumor cells or mouse liver cells 
were able of hydrolyzing beta-alanyl-melphalan extracellularly, we would expect 
beta-alanyl-melphalan to be as toxic as melphalan to mouse Ehrlich ascites tumor 
cells and mouse liver cells. Although in general, beta-alanyl-melphalan did not 
appear to be a more effective agent than melphalan against mouse Ehrlich ascites 
tumor cells, the covalent linking of melphalan to beta-alanine permitted retention 
of the antitumor potential of melphalan.
Further comparisons of cytotoxic effects of melphalan and beta-alanyl- 
melphalan in mouse liver cells revealed that beta-alanyl-melphalan was not toxic 
to mouse liver cells at any of the concentrations tested whereas melphalan was 
toxic to mouse liver cells at all concentrations tested. It is suggested that all cell 
lines tested possess amino acid transport systems which are capable of 
transporting melphalan, hence similar sensitivities to melphalan. This assumption
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is consistent with the research of Goldenberg et al. (1977; 1979), who reported 
that melphalan transport by L5178Y lymphoblasts was mediated by a carrier 
mechanism separate from that of other alkylating agents. They also reported that 
melphalan is actively transported by a mechanism that is mediated by two 
separate and distinct amino acid transport systems (the sodium dependent ASC- 
like system and the BCH-sensitive L system) in LPC-1 plasmacytoma 
(Goldenberg et al., 1979). The dipeptide (beta-alanyl-melphalan) however, was 
toxic to the mouse Ehrlich ascites tumor cells and nontoxic to the mouse liver 
cells. Since it has been demonstrated that beta-alanine containing dipeptides 
were not readily hydrolyzed by the tumor cells, it may be suggested that this 
differential sensitivity was attributable to different levels of transport.
When cancer cell populations are treated with anticancer agents (whether in 
vivo or in vitro), large changes may occur in the cell population. Many cells are 
killed by the treatment, while other cells are not affected at all, either because 
they are resistant or because of biochemical, cell cycle, or extracellular 
environmental "sanctuaries". As soon as these environmental conditions are 
reversed, the cells may express sensitivity again. Other cells, however, are 
sublethally damaged and, depending upon the accuracy and completeness of the 
recovery process, it may be assumed that the drug sensitivity of some of these 
surviving cells could be substantially different from the original population of 
cells.
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Klaassen and Stacy (1982) attempted to characterize chemical-induced 
reversible and irreversible cell injury with rat hepatocytes, focusing on parameters 
that measure membrane integrity and metabolic performance. These parameters 
included intracellular content of glutathione (GSH), calcium ion, potassium ion, 
ATP, extent of lactate dehydrogenase (LDH) leakage, lipid peroxidation, tiypan 
blue staining, and morphological alterations. The leakage of intracellular 
enzymes, such as LDH, and the uptake of trypan blue stain occur after cell death 
and thus suggest irreversible damage (Klaassen and Stacy, 1982). In contrast, 
alterations in the other parameters occur prior to cell death and indicate more 
subtle biochemical changes, which may be reversible (Klaassen and Stacy, 1982). 
Early reversible changes in cellular morphology usually include formation of blebs 
in the plasma membrane, mild cytoplasmic edema, dilation of the endoplasmic 
reticulum, slight mitochondria swelling, and marginal aggregation of nuclear 
chromatin (Jewell et al., 1982; Bridges et al., 1983). Irreversible morphological 
changes include extensive mitochondria swelling with cristae disruption, gross 
cytoplasmic swelling with dissolution of organelles, plasma membrane rupture, 
and nuclear dissolution (Bridges et al., 1983; Trump et al., 1981). Ultrastructural 
observations in the present study essentially confirmed the antitumor activity of 
melphalan and beta-alanyl-melphalan demonstrated in the biochemical assays. 
Results showed that the antitumor effects of melphalan affected the cellular 
elements causing marked cell damage both in mouse Ehrlich ascites tumor cells 
and mouse liver cells. In contrast, beta-alanyl-melphalan appeared to affect the 
cellular elements, with marked cell damage only, in mouse Ehrlich ascites tumor
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cells, but not in the mouse liver cells. There were obvious nuclear and 
cytoplasmic alterations in melphalan and beta-alanyl-melphalan treated mouse 
Ehrlich ascites tumor cells, i.e. peripheral thickening of chromatin material in 
nuclei, severe mitochondrial alterations, ribosome accumulation and autolysis 
phenomena which lead to the destruction of the subcellular structures.
At this point it was considered whether melphalan and beta-alanyl-melphalan 
were endowed with double cell localizations, at nuclear and cytoplasmic levels, 
acting with different mechanisms. Alternatively the nuclear alteration, following 
DNA alkylation, may be considered the only mechanism of all alterations 
observed both at the nuclear and cytoplasmic level. It must be considered that 
the electron micrographs showed almost simultaneous lesions in the nucleus and 
in the cytoplasmic organelles. This observation might support the hypothesis of 
the double mechanism of action occurring simultaneously at the level of the 
nucleus (alkylation) and of the cytoplasm (inhibition of protein biosynthesis).
Events that lead to death of an animal, due to chemical exposure, are related 
to the loss of cellular functions. Although the damage may be expressed as the 
loss of specific organ function, what happens to cells in that organ to cause cell 
death is a very important aspect of in vivo toxicity. Thus, for cytotoxic events to 
be better understood, they need to be examined with both in vivo and in vitro 
models. Reversible injury can cause acute toxic effects, and such toxicity, whether 
at the intact animal, organ, or cellular level, is still poorly understood in terms of
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how many cells can undergo reversible damage in vivo and allow animal survival 
after injury. Irreversible events leading to cell death involve a large number of 
cells prior to loss of organ function.
If one think of cells as being characterized by their ability to isolate 
themselves from their environment, then one can say that membrane 
compartmentation protects and enables the cell to maximize its survival.
However, one does not know whether loss of membrane compartmentation is the 
most critical aspect of cell death due to acute toxicity. Portions of the scanning 
electron microscopic evaluation of melphalan and beta-alanyl-melphalan toxicity 
indicated an alteration in plasma membrane organization after melphalan 
treatment, i.e. a loss of membrane compartmentation.
Weight loss in cancer patients is of major concern because it often leads to 
the development of fatal cachexia (Costa, 1977). The average tumor burden in 
these patients is reported to be approximately 5% of total body weight 
(Waterhouse, 1987). In contrast, experimental malignant tumors often grow to 
approximate 30 to 40% of total body weight (Mider, 1948), and the effects on 
host weight and spontaneous food intake are not normally detected until the 
tumor constitutes about 5% of total body weight (Morrison, 1984). Our results 
confirmed those of both Mider and Morrison and revealed that the average body 
weight of cancerous mice increased by approximately 16% of original body weight 
at the seventh day after tumor cell injection and that the increased body weight
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affected the water and food consumption, yielding an approximately 24% 
decrease in water consumption and a 17% decrease in food consumption. 
Morrison et al. (1984) examined mass loading effect independent of tumor growth 
using a subcutaneously implantable capsule that could be progressively filled with 
sterile saline, simulating tumor growth. Compared to the effects of a 
MCA-induced sarcoma, the implantable inert mass, although increasing the total 
body weight of the animal, contributed up to 30% of the observed decrease in 
host actual body weight and up to 20% of the observed decrease of spontaneous 
food intake at an average inflated capsule weight of 77 g. However, compared to 
controls during slow capsule inflation the deficit in weight gain was only 11% 
while depression in food intake was only 15% of that at maximum inflation 
(Morrison, 1984). The average body weight of noncancerous mice in the present 
study remained the same (31.59 gm) over the 30 day experiment period whereas 
the average total body weight of cancerous mice increased by approximately 
100% of original body weight. Without the study of Morrison, it might have been 
assumed that the increased body weight was totally due to the tumor cell growth 
and ascites fluid production. According to Morrison (1984) however, our 
assumption might underestimate the tumor mass (subtracting the weight of the 
original weight of the cancerous mouse from the final weight of a cancerous 
mouse is not an accurate means of estimating cancer mass), and thus lead to an 
overestimation of the effects of the increased body weight on depression of the 
food and water consumption. Kawashima et al. (1988) investigated a 
carrageenan-induced benign tumor which influenced food intake and decrease
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body weight in the rat, as is commonly observed with malignant tumors. 
Carrageenan-induced benign tumors reached masses of about 40 g, 21 days after 
injection. During this period, average daily food intake, carcass weight gain, 
serum albumin and liver weight were significantly lower in the study rats versus 
the control animals. Results presented in the present study revealed that average 
body weight increased 58%, 15 days after tumor injection and water consumption 
and food consumption were significantly decreased (by approximately 40% and 
50%, respectively).
Many anticancer agents are characterized by a narrow therapeutic range, 
reflecting their failure to discriminate effectively between target and normal 
tissues. Based on the results from the cell culture toxicity assays, it indicated that 
the reduced toxicity of beta-alanyl-melphalan to the noncancerous cells was the 
result of reduced cellular accumulation of the bifunctional alkylating agent, 
melphalan. If this assumption is correct, beta-alanyl-melphalan should retain its’ 
anticancer activity, yet exhibit reduced toxicity to the tumor bearing mice.
In in vivo chemotherapy assays, the antitumor activity of melphalan was 
either similar to or greater than that of beta-alanyl-melphalan at all 
concentrations used against mouse Ehrlich ascites tumor cells. Results presented 
in this study revealed that chemotherapeutic doses of melphalan, at all levels 
shown not to be lethal to the tumor bearing mice, were very effective in 
restricting development of the "tumor". Results were consistent with the known
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anticancer activities of this drug (melphalan). Beta-alanyl-melphalan did not 
appear to be a more effective anticancer agent than melphalan, since at 
equivalent concentrations melphalan constantly demonstrated greater antitumor 
activities (both in vivo and in vitro). However, beta-alanyl-melphalan was 
demonstrated to possess significant anticancer activity at doses also shown not to 
be lethal to the tumor bearing mice. Therefore, beta-alanyl-melphalan appeared 
to possess similar or slightly less antitumor activity, as compared to melphalan, 
but was also less toxic towards to the animal. These observations were consistent 
with the observed reduced chemical reactivity, increased stability, and differential 
cellular toxicities of beta-alanyl-melphalan. That the phenomenon, was not due 
simply to the use of dipeptides, was confirmed by the absence of anticancer 
activity by beta-alanyl-L-leucine and beta-alanyl-aminoethyl phosphonic acid. The 
latter of which contained the antimetabolite aminoethyl phosphonic acid. We 
suggest that the reduction in hydrolyzability of beta-alanyl-melphalan explains the 
lower T /C  ratios found for beta-alanyl-melphalan treated mice compared with 
melphalan treated mice. Our study of the sensitivity of mice to melphalan and 
beta-alanyl-melphalan have indicated that beta-alanyl-melphalan had a lower 
toxicity than melphalan. Beta-alanyl-melphalan had no observable toxic effects at 
concentration of 40 mg/kg in mice whereas, 15 mg/kg of melphalan has been 
reported as toxic to the animals (De Barieri and Dall’asta, 1983). These 
observations clearly supported the hypothesis that some neoplastic cells are 
capable of small peptide transport whereas non-neoplastic liver cells are not 
capable of transporting small peptides.
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In summary, the synthetic dipeptide beta-alanyl-melphalan represents a new 
bifunctional alkylating agent in the nitrogen mustard group of anticancer drugs. 
This dipeptide consists of a beta-alanine residue in the L-configuration with a 
bis-(2-chloroethyl)amino group in the para-position of the benzene ring of the 
phenylalanine residue. The antitumor activity could be accounted for by a variety 
of mechanisms, i.e. DNA cross linking and enzyme inactivation. It is possible that 
beta-alanyl-melphalan could directly affect tumor cell growth as well as metastatic 
potential of the tumor.
Based on the results presented in this study, the following points appear 
reasonable:
1.) The inclusion of the amino acid residue beta-alanine in the N-terminal 
position reduces the susceptibility of the beta-alanyl-melphalan to hydrolysis by 
peptidohydrolytic enzymes and reduces chemical decomposition of melphalan. 
Both characteristics may serve to enhance the body half-life of this particular 
peptide.
2.) Melphalan and beta-alanyl-melphalan chemically react with enzymes, i.e. 
L-leucine aminopeptidase, and may thus possess cellular toxicity and reduce 
cancer metastasis by restricting activities of hydrolytic enzymes.
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3.) Melphalan is toxic towards both neoplastic and non-neoplastic cells 
whereas, beta-alanyl-melphalan is toxic only towards neoplastic cells/or 
undifferentiated cells in culture. Beta-alanyl-melphalan is not toxic towards 
cultured mouse liver cells and possibly other non-neoplastic cells provided it is 
not administered orally -  where it may be toxic to the cells lining the small 
intestine. Toxicity towards the kidney may be possible regardless of the route of 
administration.
4.) The dipeptide, beta-alanyl-melphalan, exerts a differential toxicity towards 
the mouse Ehrlich ascites tumor cells, as compared to the mouse liver cells, and 
indicates a potential for different transport activities for the dipeptide.
5.) Melphalan and beta-alanyl-melphalan demonstrate nuclear and 
cytoplasmic alterations which lead to the destruction of the mouse Ehrlich ascites 
tumor cells.
6.) Melphalan is an effective anticancer drug when used in the 
chemotherapeutic treatment of mouse Ehrlich ascites tumors with a narrow range 
of safe dosage. Beta-alanyl-melphalan is also an effective anticancer drug and is 
less toxic than melphalan to the tumor bearing mice.
We conclude that the results of this study were significant in that small 
peptides containing antimetabolite served to identify a new and exciting approach
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to the targeting of anticancer drugs towards neoplastic cells. The research needs 
to be expanded to include other tumors, solid as well as ascites, human versus 
animal, and tumors at different sites in the body, i.e. vascularized versus non­
vascularized. In short, research utilizing small peptides containing antimetabolites 
needs to be expended into phase II and clinical trial studies.
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